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ABSTRACT
Characterization of Beryllium as a Novel Agent to Study Cell Cycle Arrest
and Cellular Senescence

By
Priyatham Gorjala

Dr. Ronald K. Gary, Examination Committee Chair
Associate Professor, Biochemistry
Department of Chemistry
University of Nevada, Las Vegas

Cancer

cells

evade senescence, apoptosis,

and other

constraints

proliferation, often via mutation of the p53 tumor suppressor gene (TP53).

on

Normal

human lung fibroblasts have been shown to enter premature senescence upon exposure
to beryllium. In these cells, BeSO4 stabilizes p53 protein, increases p21 gene
expression, induces senescence-associated β-galactosidase activity and causes cell
proliferation arrest. In the present study, we have investigated whether BeSO4 is able to
induce similar effects in cancer cells that have wildtype p53. We have demonstrated that
beryllium salt at low concentration can induce molecular changes in the p53 signaling
pathway leading to cell cycle arrest in beryllium-sensitive cancer cells. The p53
transcription factor is the central regulator of the mammalian DNA damage response.
However, unlike most agents that activate p53, beryllium did not cause DNA damage.
We have discovered that the growth arresting effects of beryllium are mediated through
the p53-dependent p21 pathway. We have also found that BeSO4 may be influencing the
regulation of cyclin E2, a cyclin that controls passage of cells from G1 to S phase of the
iii

cell cycle. Increased caspase 3/7 activity was also seen in response to BeSO4 treatment.
However, the number of cells undergoing apoptosis was not proportional to the activity
of caspase 3/7, suggesting that the beryllium response is primarily cytostatic rather than
apoptotic. These observations indicate that beryllium suppresses cell proliferation
through a senescence-related p53 signaling pathway that differs from the DNA damage
response pathway. These unusual properties make beryllium salt a potent tool to
investigate p53-mediated growth control pathways in both normal and cancerous cell
types.

iv

ACKNOWLEDGEMENTS
During the last 6 years I have spent in Las Vegas, many people contributed in
small and big ways that have ultimately allowed to me to successfully complete the
Ph.D. program. I would like to thank all those people who have helped me through this
journey.
First of all I am profoundly indebted to my advisor Dr. Ronald K Gary, a true
personification of mentorship. He has been very generous with his time from day 1.
Through countless hours spent in long meetings he has inculcated and honed scientific
thinking in me. He has also taught me good laboratory methods and nuances that would
be otherwise difficult to learn. I always left our meetings with a renewed motivation,
confidence and direction.
I would like to thank my committee members, Drs. Bryan L. Spangelo, Ernesto
Abel-Santos, Dong-Chan Lee and Frank van Breukelen for their support and feedback. I
also would like to thank Dr. Dennis W. Lindle (Chair, Dept of chemistry), Dr. Kathleen A.
Robins (Graduate Coordinator, Dept of chemistry) for supporting me with Teaching
Assistantship.
I want to express my gratitude to Ms. Swapna Mudireddy and Mr. Ata ur Rahman
Mohammed Abdul for all the help in the laboratory work and for being great colleagues. I
would like to thank Ms. Casey Hall and Ms. Shirley Shen at the UNLV Genomics Core
lab for their professional help.
I greatly appreciate my friends Drs. Vamsee Krishna GK, Raja Ram Chamala,
Ramesh Boggula, Venkateshwar Madka and Mr. Nageswara Rao, for their unlimited
support and encouragement whenever I needed it. I would like to thank Dr. Mukund, Mr.
Balaji, Mr. Sharath, Mr. Suman, and Ms. Pallavi for helping me settle down in Las Vegas
and making my time here a memorable experience.

v

Finally, I could not have done this without my family. I cannot thank my mom, dad
and brother enough for their unconditional love and support. I feel so fortunate to have
my wife Padma with me to go through this journey together.

vi

TABLE OF CONTENTS
ABSTRACT ...................................................................................................................................... iii
ACKNOWLEDGEMENTS ................................................................................................................ v
LIST OF TABLES ............................................................................................................................. x
LIST OF FIGURES ...........................................................................................................................xi
CHAPTER 1 INTRODUCTION ........................................................................................................ 1
PURPOSE OF STUDY ............................................................................................................ 1
RESEARCH QUESTIONS ....................................................................................................... 2
CHAPTER 2 REVIEW OF LITERATURE ........................................................................................ 3
BERYLLIUM ............................................................................................................................. 3
p53 ........................................................................................................................................... 5
CELL CYCLE ARREST, SENESCENCE AND APOPTOSIS .................................................. 6
Cell cycle arrest................................................................................................................... 6
Senescence ........................................................................................................................ 7
Apoptosis ............................................................................................................................ 8
CHAPTER 3 BERYLLIUM SENSITIVITY OF CANCER CELL LINES - CELL LINE SURVEY ..... 10
INTRODUCTION ................................................................................................................... 10
MATERIALS AND METHODS ............................................................................................... 11
Cell culture media ............................................................................................................. 11
Cell lines ............................................................................................................................ 11
Cell culture and CyQuant assay ....................................................................................... 11
Data analysis ..................................................................................................................... 13
RESULTS............................................................................................................................... 13
DISCUSSION ......................................................................................................................... 14
CHAPTER 4 BERYLLIUM INDUCES SENESCENCE LIKE STATE IN GENETICALLY
SENSITIVE TUMOR CELL LINES – COMPARATIVE STUDY BETWEEN A172 AND RKO ....... 20
INTRODUCTION ................................................................................................................... 20
MATERIALS AND METHODS ............................................................................................... 22
Cell Culture ....................................................................................................................... 22
Beryllium treatment ........................................................................................................... 22
UV and IR treatment ......................................................................................................... 22
Cell count experiment ....................................................................................................... 23
Western Blot analysis........................................................................................................ 23
Real time PCR .................................................................................................................. 24
Flow cytometry .................................................................................................................. 25
Inductively coupled plasma mass spectrometry (ICP-MS) ............................................... 25

vii

Senescence associated β-galactosidase activity assay ................................................... 26
Fluorescent microscopy H2AX ser 139 phosphorylation .................................................. 26
Statistical Analysis ............................................................................................................ 26
RESULTS............................................................................................................................... 26
Beryllium dosing stops tumor cells from dividing .............................................................. 26
Beryllium causes G1 block in tumor cells ......................................................................... 27
Beryllium causes an increase in p53 and p21 in tumor cell lines ..................................... 27
Beryllium treatment causes SA β–gal expression in tumor cells ...................................... 31
Beryllium does not cause DNA double strand breaks ...................................................... 31
DISCUSSION ......................................................................................................................... 36
CHAPTER 5 CELL CYCLE INHIBITING EFFECTS OF BERYLLIUM ON CANCER CELLS ARE
P53 DEPENDENT.......................................................................................................................... 41
INTRODUCTION ................................................................................................................... 41
MATERIALS AND METHODS ............................................................................................... 43
Cell lines and reagents ..................................................................................................... 43
Cell count experiment ....................................................................................................... 44
mRNA quantification by RT-PCR ...................................................................................... 44
Western blotting ................................................................................................................ 45
Cell cycle analysis by flow cytometry ................................................................................ 45
DNA synthesis and total DNA content .............................................................................. 45
RESULTS............................................................................................................................... 46
Three methods to knock down p53 mRNA or protein ....................................................... 46
Functional p53 makes A172 cells sensitive to growth inhibition by beryllium................... 48
Beryllium induced accumulation of cells at G1-S phase and decrease in DNA synthesis is
p53 dependent .................................................................................................................. 48
Beryllium induced p21 increase is dependent on p53 protein .......................................... 51
Cyclin E1 and E2 levels are inversely related to functional p53 protein levels ................. 54
DISCUSSION ......................................................................................................................... 58
CHAPTER 6 BERYLLIUM INDUCED CASPASE 3/7 DOES NOT CAUSE APOPTOSIS ............ 61
INTRODUCTION ................................................................................................................... 61
MATERIALS AND METHODS ............................................................................................... 63
Cell Culture ....................................................................................................................... 63
Drug treatment .................................................................................................................. 63
Caspase assay.................................................................................................................. 63
TUNEL assay .................................................................................................................... 64
DNA synthesis, Metabolism and Cell number .................................................................. 64
Statistical Analysis ............................................................................................................ 64
RESULTS............................................................................................................................... 65

viii

Staurosporine, Camptothecin and Etoposide induce caspase 3/7 in A172 and RKO ...... 65
Beryllium induces caspase 3/7 in A172 but not RKO ....................................................... 65
Beryllium can induce caspase 3/7 in A172 and HFL-1(Y) but not in HFL-1 (S) ............... 68
Functional p53 is required for beryllium to induce caspase3/7 ......................................... 68
Beryllium induced caspase3/7 may not cause cell death in A172 and HFL-1(Y) cells ..... 68
Beryllium induced caspase does not lead to Apoptosis.................................................... 72
Beryllium induced inhibition of DNA synthesis is reversible ............................................. 72
DISCUSSION ......................................................................................................................... 75
CHAPTER 7 SUMMARY AND FUTURE DIRECTIONS ................................................................ 78
SUMMARY ............................................................................................................................. 78
FUTURE DIRECTION............................................................................................................ 78
APPENDIX I CHARACTERIZATION OF AN ALTERNATIVE +/- p53 HUMAN GLIOMA MODEL
SYSTEM (U87MG)......................................................................................................................... 81
APPENDIX II CHARACTERIZATION OF A SPONTANEOUSLY-ARISING Be-RESISTANT
CLONAL DERIVATIVE OF A172 ................................................................................................... 86
APPENDIX III EVALUATION OF p53 AND p21 STATUS AND RESPONSE TO BERYLLIUM
TREATMENT IN BV CELL LINES ................................................................................................. 91
APPENDIX IV OPTIMIZATION OF siRNA FOR p53 KNOCK DOWN AND GENERATING
STABLE p53 KNOCK DOWN shRNA A172 CLONES .................................................................. 97
APPENDIX V BERYLLIUM ON THE ACTIVITY OF GSK 3 BETA .............................................. 103
APPENDIX VI TUNEL ASSAY PROTOCOL ............................................................................... 109
REFERENCES ............................................................................................................................. 113
VITA ............................................................................................................................................. 122

ix

LIST OF TABLES
Table 2-1 Properties of beryllium compounds ................................................................................. 3
Table 3-1 IC50 values of BeSO4 for different cell lines .................................................................. 18
Table 3-2 p53 status of different cell lines used in the survey ....................................................... 19
Table 6-1 Apoptotic genes upregulated in beryllium treated HFL-1 cells ...................................... 62

Appenedix II
Table 1 Cytostatic concentrations for Iso cell types ....................................................................... 87
Table 2.Cell doubling times ............................................................................................................ 87

x

LIST OF FIGURES
Figure 2-1 Overview of effects of p53 .............................................................................................. 7
Figure 3-1 Beryllium sensitive cell lines ......................................................................................... 15
Figure 3-2 Beryllium resistant cell lines ......................................................................................... 16
Figure 4-1 Cell count after 5 day beryllium treatment .................................................................... 28
Figure 4-2 Beryllium can induce G1-S accumulation of cells ........................................................ 29
Figure 4-3 Beryllium can induce p53 and p21 in senesitive cell types .......................................... 30
Figure 4-4 Beryllium causes changes in p21 gene expression .................................................... 32
Figure 4-5 SA β-gal is induced in sensitive cancer cell types by beryllium ................................... 34
Figure 4-6 Beryllium does not cuase DNA damage ....................................................................... 37
Figure 4-7 Differential uptake of beryllium is not a cause for difference in A172 and RKO
sensitivities ..................................................................................................................................... 38
Figure 5-1 Downregulation of p53 protein siRNA and shRNA ....................................................... 47
Figure 5-2 Presence of functional p53 sensitizes cells to beryllium .............................................. 49
Figure 5-3 Beryllium induced accumulation of cells in G1-S phase and DNA synthesis block
requires functional p53 protein ....................................................................................................... 50
Figure 5-4 BeSO4 up-regulation of p21 in p53 dependent manner .............................................. 52
Figure 5-5 BeSO4 requires functional p53 for p21 mRNA increase .............................................. 53
Figure 5-6 Cyclin E1 and E2 mRNA levels are lower in cells with high p53 protein. ..................... 55
Figure 5-7 p21 protein expression is dependent on p53 protein ................................................... 56
Fig 5-8 Effect of BeSO4 on Cycin E2 protein expression is correlated with p53 status in A172 cell
line .................................................................................................................................................. 57
Figure 6-1 Staurosporine, Camptothecin and Etoposide induce caspase 3/7 in both A172 and
RKO................................................................................................................................................ 66
Figure 6-2 Beryllium induces caspase in A172 but not RKO ......................................................... 67
Figure 6-3 Beryllium can induce caspase 3/7 in A172 and HFL-1(Y) but not in HFL-1 (S) ........... 69
Figure 6-4 Functional p53 is required for beryllium to induce caspase3/7 .................................... 70
Figure 6-5 Beryllium induced caspase can be inhibited by QVDOPH ........................................... 71
Figure 6-6 Beryllium induced caspase does not lead to Apoptosis ............................................... 73
Figure 6-7 Beryllium induced inhibition of DNA synthesis is reversible ......................................... 74

Appendix I
Figure 1 U87MG Cal, Neo and E6 cell counts ............................................................................... 83
Figure 2 U87MG Cal, Neo and E6 Western .................................................................................. 83
Figure 3 U87MG Cal, Neo and E6 p21 gene expression RT PCR data ........................................ 85

xi

Appendix II
Figure 1 Iso cell types are resistant to beryllium compared to A172 ............................................. 85
Figure 2 Cell doubling time of Iso cell type is greater than A172................................................... 88
Figure 3 Cytostatic concentration of beryllium ............................................................................... 89

Appendix III
Figure 1 Cell count data for BV cells .............................................................................................. 93
Figure 2 p53 and p21 status in BV cell types ................................................................................ 94
Figure 3 p21 gene expression in p53 knock down BV cell line...................................................... 95
Figure 4 p21 gene expression in p53 knock down BV cell line...................................................... 96

Appendix IV
Figure 1 Nuclear localization of fluorescent tagged Oligos............................................................ 98
Figure 2 p53 protein screening in KO cells using western blot ...................................................... 99
Figure 3 Optimization of Lipofectamine 2000 and Oligo concentrations ..................................... 100
Figure 4 p53 protein screeing of A172 p53 shRNA knock-down clones ..................................... 102

Appendix V
Figure 1 Expression of total GSK, pGSK3β and pGS in 6 different cell lines .............................. 104
Figure 2 Tau(C-17) protein expression in A172, HFL-1 and PC12 ............................................. 106
Figure 3 pTau (Ser 396) in PC12 cells......................................................................................... 107
Figure 4 Actin levels to check total protein normalization ............................................................ 108

xii

CHAPTER 1 INTRODUCTION
PURPOSE OF STUDY

Beryllium (Be2+) is a divalent cation that has the ability to inhibit growth of various
cell lines. The exact mechanism of action as to how beryllium causes cell cycle arrest or
shows anti-proliferative effect is not clearly understood. It has been demonstrated that
Be2+ in extremely low doses over short duration increases p21 mRNA and in long
exposures can induce expression of senescence-associated β-galactosidase activity in
Human fibroblasts (HFL-1) (Coates et al., 2007). The aim of this study is to improve our
understanding of the mechanism of action of beryllium salt as a cytostatic agent.
•

Chapter 3 presents the results of a survey on the effect of beryllium on various
cancer cell lines and identifies a beryllium sensitive and a resistant cell line for further
study.

•

Chapter 4 covers the data from a study that was done to evaluate the effect of
beryllium on susceptible cancer cell line. Beryllium was found to be able to induce
senescence-like cell cycle arrest through a pathway that may be different from DNA
damage pathway.

•

Chapter 5 includes data that demonstrates p53 dependence of the effects of
beryllium especially p21 increase and cell cycle arrest. The experiments were done
using A172 cell line (human glioblastoma) with p53 expression or function knocked
down using 3 different techniques (i.e., siRNA, shRNA and E6 protein expression.)

•

Chapter 6 documents the results of experiments done to analyze the level of
caspase 3/7 activation and to verify if the activation of caspase 3/7 results in
apoptosis.
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RESEARCH QUESTIONS

Beryllium can induce growth arrest in different types of cell lines. The existing
evidence indicates that it may be using p53-p21 pathway to achieve this. In this thesis
we have attempted to answer the following research questions:
1. Research question 1: Does beryllium induce growth arrest equally in various cell
types?
Test: Survey 12 cell lines exposed to eight different concentrations of beryllium
ranging from 0-1000µM over a period of 5 days and count the total number of attached
cells present at the end of growth period using Cy-Quant assay.
2. Research question 2: Does beryllium dosing induce expression of p21 and
senescence in cancer cell lines similar to HFL-1 cells?
Test: Using a beryllium sensitive and a resistant cell line as representatives of
the respective groups investigate the changes in expression of p21 mRNA and protein
levels, measure the amount of beryllium uptake by using ICP-MS, quantify the
expression of SA β gal.
3. Research question 3: Is p21 induction and cell cycle arrest induced by beryllium
a p53 dependent change?
Test: Knock down p53 expression using siRNA, shRNA and E6 protein
expression. Use the resulting cell types to study the short term and long term changes in
molecular events like p21 upregulation and other cell cycle regulator proteins and gene
expression.
4. Research question 4: Does beryllium induce apoptosis?
Test: Measure the activation of caspase 3/7 in cells exposed to beryllium and
evaluate the extent of apoptosis using TUNEL assay.
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CHAPTER 2 REVIEW OF LITERATURE
BERYLLIUM

Beryllium was discovered by Nicholas-Louis Vauquelin in the year 1797. It was
first separated in 1828 independently by a French chemist AntoineAlexandre-Brutus
Bussy and German chemist Friedrich Wöhler (De Laeter et al., 2003).
Beryllium (Be) is an alkaline earth metal with atomic number 4. It belongs to
Group IIA of the periodic table and has two oxidation states, Be(0) and Be(+2). Due to
high reactivity of beryllium it is available in approximately 45 mineral forms of which
Beryllium aluminium silicate (beryl), 3BeO.Al2O3.6SiO2 and Bertrandite (4BeO.
2SiO2.H2O) are the two commercially important ones.
Chemical
Formula

Molecular
Weight

Physical State

Be

9.012

Solid, hexagonal
structure

Insoluble

Beryllium fluoride

BeF2

47.01

Glassy,
hygroscopic
mass

Very
soluble

Beryllium
chloride

BeCl2

79.92

Needles

Very
soluble

Beryllium
hydroxide

Be(OH)2

43.03

Amorphous
powder
or
crystalline solid

Sparingly
soluble

BeO

25.01

Amorphous
powder

Very
sparingly
soluble

Beryllium
phosphate

Be3(PO4)2

271.03

Crystals

Soluble

Beryllium
sulfate **

BeSO4.4H2O

177.13

Tetragonal
crystals

Soluble

Name

Beryllium

Beryllium oxide

Table 2-1 Properties of beryllium compounds
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Solubility
in Water

Beryllium is one of the lightest metals. It has a high charge-to-radius ratio and
forms covalent bonds. Physical properties and solubility of beryllium compounds are
summarized in Table 2.1.There are nine known radioisotopes of beryllium of which
beryllium-7 (Be-7) and beryllium-10 (Be-10) are stable with half lives of 53.29 days and
1.51x106 years (C. R. Hammond, 2011-2012).
The very first observation of the ability of beryllium to stop cellular growth was
documented in 1949, using an animal limb regeneration model (Chèvremont and Firket,
1951; Thornton, 1949). Two years later, the first anti-mitotic effects in a cultured cell
system were reported in Nature (Chèvremont and Firket, 1951). Historically most of the
studies on beryllium and its effects on cells have been done with an objective to evaluate
the toxicity of the molecule and diseases associated with chronic exposure to it (Reeves
et al., 1967; Schepers, 1961). Typically, such toxicity studies employ metallic beryllium,
or beryllium salts at very high concentrations. In contrast, only a few studies have been
done to understand the mechanism of action of low dose beryllium salt as a cell
proliferation inhibitor (Skilleter et al., 1983; Skilleter and Paine, 1979; Williams and
Skilleter, 1983). In our research we have attempted to study the effect of beryllium on
cancer cells. For experiments we have used beryllium sulphate tetrahydrate, a soluble
form of beryllium. We have used beryllium at very low concentration (approximately 10
µM) in short time points between 2-7days. Our research focus was on the effect of
beryllium at low dose, short time point exposures resulting in specific responses in the
form of gene expression, cell cycle arrest etc. We have discovered that beryllium, just
like traditional chemotherapy drugs or radiation, can bring about cell proliferation arrest
or increase in p53 and p21 proteins. However, unlike the actions of chemotherapeutics
and radiation, these responses due to beryllium are stronger and without DNA damage
(Gorjala and Gary, 2010).
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p53

Two different types of studies, one using virologic approach and the other with a
serologic approach led to the discovery of p53 in the year 1979 (DeLeo et al., 1979;
Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979; Rotter et al.,
1980). Observations made immediately after discovery of p53 suggested that it may be
anti-oncogenic. Data from research in the subsequent years showed that wild type p53
genes were growth suppressive and several cancer cell lines had mutations in p53 gene.
For example HeLa cells expressed normal levels of p53 mRNA but undetectable levels
of protein (Crawford et al., 1981). Human promyelocytic leukemia cells, HL-60, has p53
gene with large deletions that results in no p53 protein expression (Wolf and Rotter,
1985). These discoveries led to identification of anti-oncogenic and normal function of
p53.
The p53 gene (called TP53) is located on the short arm of chromosome 17
(17p13) (Isobe et al., 1986). The gene is 22,000 bp long with 11 exons while its mRNA is
2.2 kb (Lamb and Crawford, 1986). p53 is a 393 aminoacid protein with three
distinguishable domains. The transactivation domain is located at the amino terminus
and is targeted by proteins to regulate p53’s function as transcription factor. The DNA
binding region of p53 is located in the central part of the protein. DNA binding region is
followed by an oligomerization domain at carboxy terminal region that mediates
tetramerization of p53. The C-terminal region of the protein contains a negative
regulatory domain as well as lysine residues that are involved in targeting the protein to
ubiquitin based degradation by proteosome.
In recognition of the significant role of p53 protein in monitoring the integrity of
genome it has been called the “Guardian of the Genome” (Lane, 1992). Under normal
conditions the half life of p53 is between 5-30 min. When the cells are exposed to
genotoxic stress stimuli, cellular levels of p53 protein are found to increase by rapid
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stabilization. Many post translational modifications stabilize the protein and prevent it
from degradation. p53 protein activates DNA repair mechanisms, induces or inhibits
expression of many target genes (El-Deiry, 1998). p21 mRNA, expressed in a p53
dependent as well as independent manner, transcribes a cyclin dependent kinase (CDK)
inhibitor which blocks cell cycle progression.
Depending on the kind and extent of damage induced by the stress, p53 protein
can induce cell cycle arrest or trigger apoptosis. The decision between cell cycle arrest
or apoptosis depends on total amount of p53 in cells, extent of DNA damage, sub
cellular localization and other factors like post translational modifications of the protein
(Chen et al., 1996; Lassus et al., 1996; Moll et al., 1996; Ostermeyer et al., 1996). While
cell cycle arrest gives cells an opportunity to overcome damage and survive, apoptosis
kills the cells thus preventing abnormal cells from surviving. Because p53 causes two
extreme outcomes for cells it is placed under tight regulation with a very short half-life.
CELL CYCLE ARREST, SENESCENCE AND APOPTOSIS

Cell cycle arrest
A series of phases that an eukaryotic cell crosses before it divides into two
daughter cells, are together termed as cell cycle. Cell cycle is composed of Gap before
DNA synthesis(G1), DNA synthesis (S), Gap after DNA synthesis (G2) and mitosis (M).
Cells have check points during cell cycle to maintain the genomic stability. These
checkpoints ensure that all the events specific to each phase materialize before the cell
moves into the next phase of cell cycle (Hartwell and Weinert, 1989). Cell cycle may be
arrested at these checkpoints if cell does not have enough supply of growth factors or
has not repaired any cellular damage that might have occurred. Cell cycle check points
can also activate apoptosis pathway that results in removal of cells that may become
potentially tumorigenic due to failed genetic repair.
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The first cell cycle check point is at the G1-S transition. This check point is also
the most extensively studied. The cell cycle arrest at G1-S check point is initiated in
response to DNA damage. This check point provides enough time to the cell to repair
the damage and allows it to make a decision about dividing or delaying the division or
entering a G0 resting phase. During DNA damage the stabilized p53 protein introduces
G1-S arrest (Baker et al., 1990; Diller et al., 1990). p53 causes this arrest by
transcriptionally increasing the Cdk inhibitor p21 (El-Deiry et al., 1993).
Beryllium was shown to induce G1 cell cycle arrest in rat liver cells (Skilleter et
al., 1983). p53 and p21 were found to be increased by beryllium in human skin and lung
fibroblast cells (Lehnert et al., 2001; Coates et al., 2007). There were no studies so far
on the effect of beryllium on the cell cycle of cancer cell lines, until our work described in
Chapter 4 and published in 2010 (Gorjala and Gary, 2010).

Figure 2-1 Overview of effects of p53

Senescence
Cultured primary cells cease to proliferate after a specific number of divisions.
This property called as replicative senescence is natural to primary cells in culture and
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was observed in human fibroblast cells by Hayflick and Moorhead (Hayflick and
Moorhead, 1961). Senescence is different from cell growth arrest both physiologically
and morphologically. Senescence is triggered by telomere shortening that accrues with
successive rounds of cell division. Activation of p53 and pRB/p16INK4a pathways is
required for induction of senescence in human cell lines (Ben-Porath and Weinberg,
2005; Shay, 1991). Senescence-associated β-Galactosidase activity (SA- β-gal) is an
important enzymological biomarker for senescence (Dimri et al., 1995).
A study from our lab group showed that beryllium, at very low doses, can cause
dose dependent induction of premature senescence in human fibroblasts (Coates et al.,
2007). The study has shown that beryllium causes sustained increase of p53 protein and
p21 mRNA and protein on short term exposure. Increase of p16Ink4a and Senescenceassociated β-Galactosidase activity were seen during long term exposures. Recent
studies suggest that activation of p53 in tumor cells leads to tumor regression by
induction of senescence (Ventura et al., 2007; Xue et al., 2007).
In present study (Chapter 4) we have data that shows that beryllium causes cell
cycle arrest and brings about senescence-like state in A172 glioblastoma cancer cell line
at a low dose of 10 µM. In subsequent work, we found that these cell cycle effects of
Be2+ are p53-dependent (Chapter 5).
Apoptosis
The term apoptosis first proposed by Kerr et al., to describe a form of controlled
“cell deletion” (Kerr et al., 1972). Since its discovery apoptosis or programmed cell death
has been recognized as a central process required for normal development of an
organism and also to maintain homeostasis (Lockshin and Williams, 1965; Jacobson et
al., 1997; Danial and Korsmeyer, 2004). Apoptosis involves a series of energy
dependent molecular events that result in various morphological changes that are
observed and documented using light and electron microscopy (Hacker, 2000). Two
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major pathways induce and execute apoptosis: (1) extrinsic or death receptor pathway
and (2) intrinsic or mitochondrial pathway. In addition, there is also a recently discovered
T-cell mediated cytotoxicity and perforin-granzyme-dependent pathway. Caspases also
called as executioners of apoptosis are cysteine proteolytic enzymes with specificity to
aspartic acid residues. Activated caspases cut their targets next to aspartic acid residues
and can in turn activate other caspases through a cascade pathway. They disrupt
important pathways by targeting protein kinases, DNA repair and structural proteins of
the cells ultimately leading to controlled cell death (Cohen, 1997; Nicholson, 1999).
Caspase activity in the cell is tightly regulated. They are synthesized as inactive
zymogens and require to be activated to become functional. Inhibitors of apoptosis
(IAP’s) are a family of proteins that can inhibit activity of caspases to rescue the cell from
apoptosis (Fuentes-Prior and Salvesen, 2004).
Evidence from many studies during early 1990’s showed that p53 could control
apoptosis (Yonish-Rouach et al., 1991; Clarke et al., 1993; Lowe et al., 1993; Symonds
et al., 1994). However, the exact mechanism as to how p53 chooses between cell cycle
arrest, senescence and apoptosis is not yet clear. p53 is known to transcriptionally
activate the proapoptotic genes Bax, Puma, Noxa and Bid (Miyashita et al.; Oda et al.,
2000; 1994; Nakano and Vousden, 2001; Sax et al., 2002). Apart from controlling
expression of these genes, p53 is also known to regulate components of intrinsic and
extrinsic pathways of apoptosis (Owen-Schaub et al., 1995; Muller et al., 1998; Kannan
et al., 2001; MacLachlan and El-Deiry, 2002).
Our published experimental data showed increase of p53 in beryllium treatment,
so we have used caspase and TUNEL assays to evaluate whether apoptosis is induced
by beryllium treatment (Chapter 6).
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CHAPTER 3 BERYLLIUM SENSITIVITY OF CANCER CELL LINES - CELL
LINE SURVEY
INTRODUCTION

Earlier studies have documented the effects of beryllium on normal cells. One of
the very early studies of effects of beryllium used time-lapse cinematographic analysis
and found that beryllium increased the division time of human lung fibroblasts (HFL-1)
(Absher et al., 1983). Many studies around this period and earlier have linked beryllium
to two diametrically opposed effects: carcinogenesis and growth inhibition. These
studies have used various cell types including HFL-1, rat liver cells, skeletal muscle
cells, macrophages etc, and various salts of beryllium and concentration ranges. A list of
these studies can be found in paper by Wagoner et al (Wagoner et al., 1980). A study by
Hart et al (Hart et al., 1982) has documented the effect of beryllium in various forms on
growth of human lung fibroblasts. A recent study by Coates,S.S et.al has attempted to
systematically investigate the mechanism of action of beryllium. The study demonstrates
that beryllium has anti-proliferative effect on normal human lung fibroblasts (Coates et
al., 2007). The study also shows that there is an interaction between promoter of p21
gene and p53 protein that results in an increase of p21 gene. In response to beryllium
treatment the cells exhibit G1 to S phase block leading to G1 arrest.
The evidence that beryllium causes increase of p53 and p21 proteins and also
growth arrest at a very low concentration of 10 µM gave us the motivation to study the
effect of beryllium on cancer cell lines. Our expectation is that beryllium may be able to
cause a similar increase of p53 and p21 leading to growth arrest in cancer cell lines that
have functional p53 and p21 genes. The response of cancer cell lines to a drug will be
different due to the variation in genetic and phenotypic makeup of the cells. With this
idea we have conducted a survey of responses of 12 cell lines to a range of
concentrations of beryllium. The objective of this survey study is to verify if different cell
10

lines respond differently to beryllium dose and to select a representative cell line for
sensitive and resistant varieties.
MATERIALS AND METHODS

Cell culture media
RPMI glutamax-1 + 25mM HEPES Cat# 72400, PSF – Gibco antibiotic and
antimycotic Cat# 15240-062, 0.05% Trypsin-EDTA - Cat# 25300 are purchased from
Invitrogen - Gibco (Carlsbad, CA). Fetal Bovine serum - Cat# SH30071 and phosphate
buffered saline – Cat# ARC25970 are from Hyclone Laboratories (Logan, UT). Cyquant
cell proliferation kit was obtained from Molecular probes.
S91 cell line requires F-12K Medium (Kaighn's Modification of Ham's F-12
Medium). S91 cells from stock were thawed into F12K medium supplemented with 15%
calf serum, 2.5% fetal bovine serum and 1x antibiotic and antimycotic. The cells were
slowly adapted to regular RPMI medium mentioned above.
Cell lines
A172,BT4C, C6, U87MG, PC12, U251, HeLa, PC3, S91 and RKO were
purchased from ATCC (Manassas, VA). Cell lines SF539, SNB75 were purchased from
National Cancer Institute. Cells were cultured in RPMI 1640 with Glutamax and 25mM
HEPES supplemented in 10% FBS and 1%PSF.
Cell culture and CyQuant assay
Cells from 100mm plates were trypsinized using 1mL of 0.05% Trypsin-EDTA
followed by incubation for 3 minutes at 37ºC and 5%CO2. The cells were then
resuspended in 7 mL of fresh cell culture media. The number of cells was calculated
using coulter counter and reseeded as required.
Each cell line used in the experiment was seeded to 60 mm plates and allowed
to reach 100% confluency. The cells in 60 mm plates were trypsinized by adding 500 µL
of 0.05% Trypsin-EDTA and incubated at 37ºC and 5% CO2 for 3 minutes. The cells
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were resuspended in 2.5 mL RPMI. 100 µL of cell suspension was mixed with 9.9 mL of
Isoton solution and used for taking cell counts in coulter counter. This number is used to
determine the number of cells required for each cell line to reach 100% confluency.
Day -1, Seeding to 60 mm plates: The cells from 100 mm plates were trypsinized
as described before and available number of cells were determined by using coulter
counter. For each cell type the required number of cells was calculated and twenty four
60 mm plates were seeded (8 doses x 3 replicates = 24).
Day 0, Beryllium dosing: RPMI is prepared with 0, 1, 3, 10, 30, 100, 300 and
1000 µM BeSO4. 10 mL of RPMI at each concentration of BeSO4 is prepared for each
cell line. The plates seeded on day -1 are screened for uniform distribution and
confluency. Plates are shuffled, labeled and media is replaced with freshly prepared
beryllium RPMI corresponding to the labels. Adding beryllium RPMI marks the beginning
of time point and the day is counted as Day 0.
Day 3, Transfer to 96 well plate: 60 mm plates were screened to check for
confluency. The control (0µM beryllium RPMI) plates were trypsinized as described
before and cell counts determined using coulter counter. Volume of cell suspension
required to seed 16000 cells per well is calculated and mixed with RPMI to get final
volume to 200µL. The volume calculated for control plates is used for all concentrations
of BeSO4. Using the volume calculated for control cells enabled us to transfer the
number of cells proportional to the ones remaining in the plates after experiencing the
effect of beryllium. Cells from each 60 mm plate were seeded into 3 replicate wells on
the 96 well plate. The concentration of BeSO4 was maintained during the transfer of cells
from 60 mm to 96 well plate.
Day 5, Standard curve seeding and termination: Approximately 8 hours before
terminating the experiment, standard curve seeding is done. Untreated cells for each cell
line are trypsinized from a 100 mm plate and resuspended in RPMI. Cell counts are
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taken and dilutions are prepared to give 62500, 31250, 15625, 7813, 3906, 1953, 976
and 0 cells per well. The diluted cells are seeded to three replicate wells.
Experiment was terminated 8 hours after the standard curve cells were seeded.
To terminate the experiment the plates were removed from incubator and inverted in
sink to remove RPMI. 200 µL of PBS is added to wash the cells in all wells. This step is
done carefully taking precaution not to dislodge any cells. PBS is removed by inverting
the plate in sink and blotting over stack of paper towels. The 96 well plate is wrapped in
aluminum foil and saved at -80ºC till further processing.
CyQuant assay: On the day of assay the plates are removed from -80ºC and
placed on dry ice for 3 hours, contributing to a freeze-thaw cell lysis step. The plate is
allowed to thaw to room temperature and 200 µL of CyQuant solution, prepared by
mixing 19 mL Millipore water, 1 mL CyQuant cell lysis solution and 50 µL CyQuant GR
dye, is added. The plate is wrapped in aluminum foil and incubated at room temperature
for 5 minutes and readings are taken on Genios plate reader set to 486 nm and 535 nm
of excitation and emission wavelengths respectively.
Data analysis
The fluorescence reads from wells with standard curve were plotted on y-axis
with corresponding cell number on x-axis. A linear regression trend line was added and
the slope in resulting equation was used to calculate the cell number in each well.
Average of replicates is plotted for all cell lines.
RESULTS

Beryllium in the form of BeSO4.4H2O was diluted from primary stock to give final
working concentrations of 0, 1, 3, 10, 30, 100, 300 and 1000µM. The cells were cultured
in the presence of beryllium in 60 mm plates for 3 days and then reseeded to 96 well
plate as described earlier. At the end of 5 days under beryllium influence, the total DNA
content of cells in each of the wells of the 96 well plate was calculated using Cy-Quant
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assay, which employs the dsDNA dye CyQuant. The volume of cell suspension
transferred from 60 mm plates to the wells of 96 well plate is same for cells at all
concentrations of BeSO4. This ensured that the number of cells transferred to 96-well
plate are proportional to the number of cells remaining attached to the 60 mm plate at
the end of day 3. The total period of exposure to the drug was for 5 days. The
concentration of BeSO4 and the proportion of number of cells attached to 60mm plates
are maintained during the transfer of cells from 60 mm plates to the wells of 96 well
plate. This assay measures the differential growth of treated cells during the 5 day
treatment period.
The results shown in Fig 3.1 and 3.2 demonstrate that all cancer cells are not
sensitive to beryllium. Out of 12 cell lines used for this survey 6 cell lines were
considered sensitive and 6 cell lines were resistant. The classification was done based
on IC50 values of beryllium for each cell line. The IC50 value represents the
concentration of drug required to produce 50% inhibition of cell number (as judged by
total DNA content) during the growth period in the 96-well plates. A172, a human
glioblastoma cell line and SF539, a glioma cell line from human, were the most sensitive
of all the cell lines. RKO,a human colon carcinoma and PC-12, a pheochromocytoma
from rat were the most resistant.
DISCUSSION

The green fluorescent dye in the Cy-Quant reagent binds to the DNA in cells.
The amount of fluorescence is directly proportional to the number of cells in the wells.
Cells were serially diluted and seeded to generate values for standard curve. The
equation from standard curve is used to calculate the number of cells in control and
beryllium dosed wells.
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Figure 3-1 Beryllium sensitive cell lines
A172 (human, glioblastoma) and SF539 (human, glioma) were the most sensitive cell lines. Both
of these cell lines showed highest sensitivity to beryllium by showing decrease in cell number
even with IC50 values of 3.4 and 5.1 µM respectively for beryllium. The data are presented as
mean +/- Standard Deviation.
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Figure 3-2 Beryllium resistant cell lines
RKO (human, colon carcinoma) and S91 (pheochromocytoma, rat) were the most resistant cell
lines. Both of these cell lines showed resistance and ability to survive presence of beryllium with
IC50 values of 440 and 290 µM of BeSO4. The data are presented as mean +/- Standard
Deviation.
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Role of p53 in the cellular response to the treatment of cells with beryllium has
been documented in earlier studies (Gary and Kindell, 2005; Lehnert et al., 2001). Table
3.2 documents the p53 status of the different cell lines used in this survey. It is possible
that the difference in the status of p53 might have contributed to the variation in
response of cell lines to beryllium treatment. However, with the data presented here,
there is no correlation between the p53 status and beryllium resistance. A detailed study
is required to thoroughly understand the mechanism of action and also to explain the
differences in response to beryllium.
For further study about the mechanism of action of beryllium, we chose to use
human cell lines A172 and RKO as representatives of sensitive and resistant cell lines,
respectively. The choice was based on the IC50 values listed in Table 3.1. Both these
cell lines express functional p53 protein (Mirzayans et al., 2005; Ishii et al., 2006; Liu and
Bodmer, 2006).
The data presented in later chapters show that some of the effects of beryllium
include cell cycle arrest and p53 dependent induction of p21. It has been established in
earlier studies that p53 protein plays an important role in cell cycle arrest and cell lines
having mutated p53 or lacking p53 may show some resistance to action of cytotoxic
drugs (Amundson et al., 1998; Shaw, 1996; Brosh and Rotter, 2009).
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IC 50 Value
S.No

Cell Line

(µM of beryllium)

1

A172

3.4

2

SF539

5.1

3

BT4C

8.5

4

C6

8.9

5

U87MG

12

6

SNB75

22

7

PC12

56

8

U251

59

9

HeLa

72

10

PC3

180

11

S91

290

12

RKO

440

Table 3-1 IC50 values of BeSO4 for different cell lines
Different cell lines have different levels of sensitivity to beryllium treatment. Some cell lines can
tolerate very high concentration of beryllium while some are sensitive to its presence even in very
small concentrations. The IC50 values are calculated from the data used to plot Fig 3.1 and 3.2
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S.No

Cell
Line

Type, Origin

Species

ATCC Cat
#

1

A172

Glioma, Brain

Homo
sapiens

CRL- 1620

2

SF539

Glioma, Brain

Homo
sapiens

NCI-60 cell
line *

3

BT4C

Glioma, Brain

Rattus
norvegicus

4

C6

Glioma, Brain

Rattus
norvegicus

CCL-107

5

U87MG

Glioma, Brain

Homo
sapiens

HTB-14

6

SNB75

7

PC12

Pheochromocyt
oma

Rattus
norvegicus

8

U251

Glioma, Brain

Homo
sapiens

9

HeLa

Adenocarcinom
a, Cervix

Homo
sapiens

Homo
sapiens
Mus
musculus

Homo
sapiens

NCI-60 cell
line *

10

PC3

11

S91

Adenocarcinom
a; Metastasis to
bone, Prostate
Melanoma ,
Skin

RKO

Carcinoma,
Colon

12

CRL-1721

CCL-2

TP53 status

Wild Type
Single mutation,
Frame shift
mutation at
position 342
deletion of 1 A

Wild Type

Wild Type,
Homozygous
Mutant p53,
position 258 G
to A
Functional p53
protein
expressed
Mutant p53,
position 273 R
to H
p53 mRNA
expressed but
protein is
degraded due to
complexing with
HPV proteins
No p53 mRNA.
Single copy of
p53 gene has
deletion at
codon 138
resulting frame
shift placed a
stop codon at
169.

References
(Mirzayans et
al., 2005;
Ishii et al.,
2006)

(Forbes et
al., 2010)

(Asai et al.,
1994)
(Ishii et al.,
2006; Van
Meir et al.,
1994)
(O'Connor et
al., 1997)
(Eizenberg et
al., 1996)
(Brazdova et
al., 2009)

(Scheffner et
al., 1991)

CCL-53.1

(Carroll et al.,
1993; Isaacs
et al., 1991)
No ref
available

CRL-2577

(Liu and
Bodmer,
2006)

CRL-1435

Wild type p53

Table 3-2 p53 status of different cell lines used in the survey
p53 plays a significant role in the effectiveness of drugs that interfere with cell cycle controlling
pathways.
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CHAPTER 4 BERYLLIUM INDUCES SENESCENCE LIKE STATE IN
GENETICALLY SENSITIVE TUMOR CELL LINES – COMPARATIVE STUDY
BETWEEN A172 AND RKO *
INTRODUCTION

Normal somatic cells undergo cell division, after a specific number of divisions
they enter a phase called cellular senescence. Senescence is characterized by very long
population doubling times and changes in morphology of cells however, the cells are
metabolically active (Campisi, J.,2001). Replicative senescence is the name given to the
process that is a result of decreased ability of normal cells to divide due to shortening of
telomeres after multiple cell divisions (von Zglinicki, 2001). Senescence induced by
factors other than telomere shortening is known as premature senescence or
accelerated senescence. Senescence in general is believed to be a tumor suppressor
mechanism developed by cells. When normal cells undergo mutations that give them
ability to override the senescence mechanism they turn into cancer causing cells.
It is now established that some types of tumor cells can be made to become
senescent by exposing them to drugs, radiation or genetic manipulation. Some of the
therapeutic agents that are used in treatment of cancer function like senescence
inducing agents. These drugs inflict DNA damage which in turn activates the p53
dependent senescence pathways in vitro (Chang, B. D., 1999). p53 is at a pivotal point
______________________________________________________________________
* NOTE: This chapter corresponds to the content of the published paper:
Gorjala and Gary (2010). Beryllium sulfate induces p21CDKN1A expression and a
senescence-like cell cycle arrest in susceptible cancer cell types. Biometals 23: 10611073.
Two versions of this manuscript were written independently. The version of the
manuscript as it appears in Biometals was written by Dr. Ronald K. Gary. The alternate
version of the manuscript, which appears here as Chapter 4, was written by Priyatham
Gorjala.
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in intracellular signaling network that detects DNA damage and controls the progression
of cell cycle (Di Leonardo, A. et al, 1994). The p53 regulated cell cycle arrest can be
initiated by various means that include DNA damage, oxidative stress, HDAC inhibitors
etc (Drayton S et al 2002). p53 and p21 play a key role in induction of senescence in
normal cells and are also responsible for senescence in human tumor cells treated with
therapeutic drugs (Chang, B. D., 1999). p53 senses DNA damage due various stress
stimuli, short telomeres or activated oncogenes. The activated p53 mediates its cell
cycle arresting actions through p21. p21, a cyclin dependent kinase inhibitor, is famous
for its role in cell cycle arresting abilities. Many studies have proved that p21 causes G1
phase arrest in cell cycle. G1 phase arrest occurs as a result of cyclin dependent kinase
inhibition in the initial phases of senescence and the changes are coordinated by action
of p21 during the early phases of senescence (Dulić V et al., 2000).
Induction of cellular senescence pushes cells from actively proliferating state to a
non-proliferating senescent state. Induction of cellular senescence in tumor cells is being
considered as well as researched aggressively as a treatment option. Apoptosis is
another process that can be used to remove actively dividing cells from system but,
senescence is unique in that the process helps in retaining the functional cells in the
system. 5-fluorouracil, doxorubicin, aphidicolin and cisplatin are examples of many drugs
found to induce cellular senescence in tumor cells. These drugs show their effect due to
the interactions with DNA (Roninson IB et al., 2001). A simple element beryllium was
found to increase the levels of p53 and p21 (Lehnert et al., 2001). Cell cycle arresting
properties of beryllium were first reported by Hart and Skilleter et al (Hart et al., 1982;
Skilleter et al., 1983). Coates SSA et al., reported beryllium as a new premature
senescence inducing drug in normal young Human Fibroblast (HFL-1) cells for the first
time (Coates SSA et al., 2007).
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In this study we have investigated the efficiency of beryllium as senescence
inducing agent in tumor cells. Our study also shows that effects of beryllium, though very
strong even at significantly lower doses, are not due DNA damage. We also found that
effect of beryllium is not same on all cell lines but, depends on the sensitivity of cell line.
For our investigation, we have used A172 and RKO cell lines as representatives of
beryllium sensitive and resistant cell lines respectively. Beryllium is used in form of
BeSO4, which is a highly soluble form.
MATERIALS AND METHODS

Cell Culture
Wild type A172 and RKO cells were used for experiments. The cell lines were
propagated RPMI1640 with GlutaMAX supplemented with 10% fetal bovine serum and
1% PSF. The cells were cultured in 100 mm dishes at 37ºC with 5% CO2. 0.05% trypsin
EDTA was used for trypsinizing the cells when splitting.
Beryllium treatment
BeSO4.4H2O from Fluka was used to prepare a stock solution. Beryllium stock
solution was diluted to required concentration in RPMI just before dosing.
The cells for control plates and beryllium dosed plates were taken from same cell
stock and seeded to plates. After allowing the cells to attach the plates were shuffled,
labeled and media changed. The control plates receive normal RPMI with no beryllium
and the beryllium dosed plated receive respective concentration of beryllium RPMI.
UV and IR treatment
For ionizing radiation dosing, the Cabinet X-Ray system, model Rx-650, by
Faxitron X-ray corp was used. For UV dosing a 15 W UV light source (Sankyo Denki
G15T8) was used and dosage was monitored using UVX radiometer, model UVX-25.
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Cell count experiment
The cells were cultured in 60 mm plates. The dishes were seeded from single
cell stock and left for approximately 24 hours allowing the cells to attach. The plates are
then shuffled, labeled and dosed with beryllium. 72 hours after dosing the cells were
trypsinized and resuspeneded in RPMI with or without beryllium. Exactly same volume of
cell suspension from all plates was seeded to 96-well plate. Each plate was seeded in
triplicate on the 96well plate and allowed to grow for another 48 hours.
The experiment was terminated at the end of 5th day. Cell counts were obtained
by measuring fluorescence using CyQUANT Cell proliferation assay kit (Invitrogen
cat#C7026). Number of cells attached to plate was estimated using a standard curve
generated from serial diluted cells seeded into the same plate 12hrs before termination
of experiment.
Western Blot analysis
Protein extracts of cells treated with beryllium were made by in M-PER (Pierce
cat#78501) with protease (Halt protease inhibitor cocktail kit, Pierce cat#78410) and
phosphatase inhibitors (Sodium Fluoride 20 mM, Beta Glycerol phospate 10 mM,
Sodium ortho vanadate 0.1 mM, Paranitro phenyl phospate 20 mM). The cell suspension
was lysed by pippetting vigorously. The lysed cell suspension was centrifuged and total
protein concentration in supernatant was measured by using BCA assay (Thermo
scientific # 23227).
Normalized samples were loaded onto 8% gels for probing with Actin, p53 and
10% gels for probing with p21 protien levels. The gels were electrophoresed and
transferred to polyvinylidine difluoride membrane (Millipore cat#IPFL20200). The
following primary and secondary antibodies were used for probing.
p53: Mouse monoclonal IgG2a (Cat# SC-126 Santa cruz biotechnology, inc) and
Goat anti-mouse IgG peroxidase (Cat#A9917 Sigma Aldrich)
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p21: Mouse monoclonal IgG2b (Cat# SC-6246 Santa cruz biotechnology, inc)
and Goat anti-mouse IgG peroxidase (Cat#A9917 Sigma Aldrich)
Actin: Goat monoclonal IgG2b (Cat# SC-1615 Santa cruz biotechnology, inc) and
bovine anti-goat IgG-HRP (Cat# SC-2350 Santa cruz biotechnology, inc)
P53 ser 15: Rabbit polyclonal (Cat# 9284 Cell signaling technology) and Goat
anti-rabbit IgG- HRP (Cat# 31460 Thermo Scientific)
γH2AX: Rabbit IgG (Cat# DR1017 Calbiocehm) and Goat anti-rabbit IgG- HRP
(Cat# 31460 Thermo Scientific)
The blots were developed using ECL plus reagent (GE health care amersham
cat# RPN 2132). Imaging was done by using Typhoon variable mode imager with
excitation wavelent of 457nm and emission filter set to 520nm.
All experiments were setup in duplicates for checking reproducibility of the
results.
Real time PCR
Total mRNA was extracted from control and dosed cells using Rneasy Mini Kit
and QIA-shredder (Qiagen cat #74104 and 79654). Real time PCR was performed on
same quantity of cDNA sample reverse transcribed from total mRNA using QuantiTect
Reverse Transcription Kit (Qiagen cat# 205311) and QuantiTect SYBR green PCR kit
(Qiagen cat# 204143). The primers used were Actin, GAPDH, p21 (QuantiTect Primer
assays – QT00095431, QT00079247, QT00062090).
The following thermal cycling profile was used for amplification and detection Initial Denaturation at 95ºC for 15 minutes. 40 repetitions of denaturing at 94ºC for 15
seconds, Annealing at 55ºC for 30 seconds, extending at 72ºC for 30 seconds. Final
denaurataion at 95ºC was done for 1 minute and final extention was done at 72ºC 1
minute. Melt curve analysis was done starting from 55ºC for 10 seconds with increasing
set point temperature after cycle 2 by 0.5ºC.
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Flow cytometry
The control and dosed cells were trypsinized and 5 x105 cells were used for
staining with propidium iodide. Dosed cells were treated with 10 µM BeSO4 for 3 days.
The cells were washed in cold phosphate buffered saline twice and fixed using 95%
ethanol. Before staining the cells were washed in phosphate buffered saline and
resuspened in 1% Triton X-100 and treated with RNAse. The cells were stained with 100
µg/mL of propidium iodide.
Inductively coupled plasma mass spectrometry (ICP-MS)
A172 and RKO cells were seeded into 100 mm plates. After allowing the cells to
attach the media was replaced with or without beryllium as required. 0, 10, 30 or 100 µM
concentrations were used and each concentration in triplicate were setup for this
experiment. After 24 hour and 48 hour time periods the media was removed and each
plate washed 3 times with RPMI only (without FBS and PSF) and 3 times with
phosphate buffered saline. 300 µL of M-PER buffer without protease and phosphatase
inhibitors was used for each plate and cells were scrapped and transferred into 1.5 mL
tubes. The samples were vortexed vigorously and centrifuged. 250 µL of supernatant
was diluted by adding to 19.75 mL of millipore water and 10 µL was used for protein
content estimation by BCA assay. Sample of 25 mL is filtered through 0.45 micron glass
filter into a new pre-rinsed tube. A special wash control plates were also run in parallel to
monitor the washing steps. Wash control plates are treated identical to the 0µM plates in
setup, media changes and harvest except that, just before harvest the cells received
beryllium RPMI for exactly 1 minute. Reading from these plates shows the amount of
beryllium that was trapped between the cells and carried over to lysates.
Total beryllium uptake is measured by using Inductively Coupled Plasma-Mass
Spectrometer. Standard curve was setup with 0, 10, 50, 100, 500, 1000 nM of beryllium
in Millipore water. The readings taken were normalized to total protein content.
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Senescence Associated β-Galactosidase activity assay
A172 cells were setup with doses of 0 and10 µM beryllium. RKO cells were
dosed with 0,10 and 100 µM beryllium. The following HFL-1 cells were used
comparision.
HLF-1 cells at passage 16(young) and HFL-1 passage 31(senescent) at harvest
for 6 day, HFL-1 passage 18 (young) and HFL-1 passage 32 (senescent) at harvest for
12 day assay.
Senescence Associated β-Galactosidase activity (SA β-Gal activity) was
measured in protein normalized samples. The quantitative assay was performed
according to method previously described (Gary and Kindell, 2005).
Fluorescent microscopy H2AX ser 139 phosphorylation
The control and test cells seeded and dosed in lab-tek chamber slides were
washed with cold P.B.S, 3 times and fixed with 4% formaldehyde and permeabilized with
0.5% TritonX. The cells were then incubated in 10% Normal Goat Serum to prevent
nonspecific binding. Primary anti-body treatment was given for 1 hour followed by
Secondary anti-body at room temperature for 45 min in dark. ProLong gold antifade was
used to seal the coverslip to slide and then the slide was taken for imaging.
Statistical Analysis
Data sets with two dosage groups at each time point were analyzed by unpaired
t-test, two tailed. Data sets with more than two groups were analyzed using one-way
ANOVA with a post-hoc Bonferroni's multiple comparision test (P < 0.05 considered
significant).
RESULTS

Beryllium dosing stops tumor cells from dividing
Beryllium sulfate causes the human fibroblast cells to enter into a premature
senescence in a dose dependent manner (Coates SSA et al., 2007). To investigate if
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BeSO4 has similar effect on tumor cells we have used A172 and RKO cell lines for our
study. The results (Fig 4.1) show that A172 is sensitive to presence of beryllium even at
1 µM concentration where as RKO cell line is able to resist the effects even at a high
concentration of 100 µM. This simple but effective cell count experiment clearly shows
the difference in the effect of beryllium on the two cell lines. Death of cells in test
samples is not the only reason for decreased cell counts in test samples compared to
control samples. The number of cells that do not undergo cell division in test samples
cumulatively resulted in lower counts at the end of 5 day time point. When observed
under microscopes there were dead floating cells at higher concentration of beryllium
but, at lower concentrations the test plates looked almost identical to control plates with
lower confluency and lower number of mitotic cells.
Beryllium causes G1 block in tumor cells
To verify if beryllium actually causes a block in cell division we performed a flow
cytometry analysis on the sensitive cell line, A172. Total of 40,000 cells from control and
test samples were analyzed and counted. There is a 19% increase in cells blocked at G1
phase in 10 µM beryllium treated samples compared to controls (Fig 4.2). These results
show that there is accumulation of cells in G1 phase of cell cycle when A172 cells were
treated with beryllium.
Beryllium causes an increase in p53 and p21 in tumor cell lines
It is a very well established fact that increased active p53 protein in cells usually
leads to G1 block of cell cycle through p21. The western blot data (Fig 4.3) shows an
increase in p53 and also p21 proteins in A172 cell lines treated with 10 µM concentration
for 24 and 48 hours. The increase is in correlation with the observation of G1 block in
test sample made using flow cytometry data. The more resistant RKO cells on the other
hand do not show any significant changes in levels of p53 or p21 proteins. RKO cells
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Cell count after 5 day beryllium treatment
Number of cells as percent of control

150

A172
RKO

100

50

0
0 (Control) 1

3

10

30

100

300

1000

Conc of BeSO4 in µM
Figure 4-1 Cell count after 5 day beryllium treatment

After 5 days of treatment with beryllium RPMI, plates with A172 cells have significantly
lower cells even at a very small dose of 1µM. On the other hand RKO cells seem to
tolerate a very high dose of 100 µM beryllium. The data are presented as mean +/Standard
Deviation.
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Figure 4-2 Beryllium can induce G1-S accumulation of cells

Comparison between control (A) and cells treated with 10 µM BeSO4 (B) for 3 days
shows that there is an accumulation of cells in G1 phase in Beryllium treated cells.
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Figure 4-3 Beryllium can induce p53 and p21 in senesitive cell types

A. RKO cells dosed with beryllium at 0 (control), 10 and 100 µM for 24 (Day 1) and
48hours (Day 2). The dosed cells show no observable change in levels of both p21
and p53 protein compared to control cells. The last two lanes show blots of lysate
extracted from cells dosed with IR (X-ray at 5 gray) and UV (at 10 J/m2) radiation. IR
and UV lane extract shows increase in p53 and p21 protein proving the presence of
functional p53 –p21 system in the RKO cells.
B. A172 cells dosed with beryllium at 0 (control) and 10 µM for 24 (Day 1) and 48hours
(Day 2). Compared to control samples a very large increase in the amount of p21
and p53 protein is seen even at a very low dose of 10 µM BeSO4.
C. In a separate experiment cell lysate of A172 cells treated with 0 and 10 µM of
beryllium for 24 hours and 48hours was analyzed using western blot for checking the
levels of phosphorylation of p53 at ser15. The results show a clear increase in
BeSO4 treated samples
Actin levels in the samples were used to check for protein normalization accuracy.
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were treated with ionizing radiation (X-rays – 5 Gy) and UV (10 J/m2). This additional
dosing shows that RKO cells had functional p53 and p21 proteins.
To measure the changes in levels of p21 Reverse transcription polymerase chain
reaction (RT-PCR) is used (Fig 4.4). For the sensitive A172 cells a 135% and 225%
increase compared to control is seen at 24 hrs and 48hrs respectively. The resistant
RKO cells do not show increase of p21 compared to respective controls. The RKO cells
have functional p21 system which is resulting in 480% and 127% increase compared to
control when dosed with UV and IR respectively.
Beryllium treatment causes SA β–gal expression in tumor cells
Experiments by Coats SSA et al have shown that SA β–gal expression is
increased in human fibroblast cells upon exposure to low concentrations of beryllium
(Coates SSA et al., 2007). To check if a similar response is elicited in tumor cell lines,
SA β-gal assay is performed on A172 and RKO cells with HFL-1 young presenescent
and senescent cells as positive controls.
The increase in SA β-gal levels in A172 is comparable to response seen in HFL1 young cells treated with same concentration of beryllium. RKO cells on the other hand
have very less quantity of SA β-gal in control cells and show no change in SA β-gal
levels even at a high dosing concentration of 100 µM (Fig 4.5).
Beryllium does not cause DNA double strand breaks
Increase in concentration of p53 and subsequent increase of p21 is a typical
response seen in case of DNA double strand breaks. To investigate the possibility
beryllium causing DNA double strand breaks to bring about the pause in cell cycle we
checked the phosphorylation of ser 139 in H2AX. H2AX is histone protein and its
phosphorylation at ser 139 is used to identify cells with DNA double strand breaks. DNA
damaging agents Etoposide, Camptothecin and UV dosing were used to generate
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Figure 4-4 Beryllium causes changes in p21 gene expression

A.
A172 cells were treated with 0(control) and 10 µM beryllium and GAPDH and p21
levels of mRNA were measured. From the plot it is obvious that there is significant
increase in mRNA levels of p21 in beryllium dosed cells.
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C.
RKO cells were treated with 0(control), 10 µM and 100µM. The mRNA levels
measured using Real time PCR shows that, there is no significant increase in p21 even
at 100 µM dose of beryllium.
E.
To verify if RKO cells have has functional p21 genes RKO cells were exposed to
UV, IR and mRNA levels measured.
B,D,F Actin is a house keeping gene used and GAPDH mRNA levels were used to
normalize the data.
The data are presented as mean +/- Standard Deviation. Statistically significant
differences are indicated as * P < 0.05, ** P < 0.01, *** P < 0.001.

33

Figure 4-5 SA β-gal is induced in sensitive cancer cell types by beryllium

Fluorescence readings were taken at the end 12 day treatments on cell lysates at
0,30,60,90,120 minute time points. The data presented here is from reading taken at the
end of 120 minutes. The signal was strongest at end of 120 minutes and the signal
strength at other time points was relatively weak but proportional to the data shown here.
HFL-1 senescent cells were generated by propagating the young cells till they reached
passage 35 by the time of harvest. HFL-1 used as positive control for the assay. A172
Young cells were at passage 18 by the time of harvest. The young HFL cells were
treated with 10 µM and cells were treated with 10 µM beryllium and RKO cells were
given a low dose of 10 µM and high dose of 100 µM beryllium.
The levels of SA β-gal levels were measured by using 4-methylumbelliferyl-β-dgalactopyranoside (MUG). The final values of fluorescence are normalized to the total
protein content of the respective samples. The data are presented as mean +/- Standard
Deviation. Statistically significant differences between control and treatment groups are
indicated as * P < 0.05, ** P < 0.01, *** P < 0.0001.
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positive control samples for western blot and etoposide only for immunofluorescence
experiments.
Both 24 and 48 hours treatment even at a very high concentration of 300µM
beryllium failed to show any increase of H2AX ser 139 phosphorylation. The positive
controls, Etoposide, camptotehcin at 10 µM each for 24 hours and UV dosed samples,
on the other hand have shown significant increase of H2AX ser 139 phosphorylation (Fig
4.6).
Immunofluorescence microscopy is usually used to check for Ser 139
phosphorylation in H2AX. Our experiments with 10 µM and 300µM beryllium for 24
hours have resulted in images looking similar to control samples while bright foci can be
seen in positive control i.e., 10 µM Etoposide samples.
Both Western blotting and Immunofluorescence microscopy results show that
BeSO4 even a very high concentration of 300µM may not be inducing any double strand
breaks.
All the observations made in the above experiments show that A172 is affected
by beryllium more than RKO. ICP-MS was used to measure the intracellular
concentration of beryllium in each cell line (Fig 4.7). This was done to find out if there is
any difference in uptake of beryllium by the cell lines that is resulting in the difference in
sensitivities. The final values of beryllium concentration inside the cells were normalized
to the total protein content of the cells used for experiment. At a lower concentration of
10 µM A172 cells appear to be taking up more beryllium compared to RKO cells but, at
higher concentration of 100 µM both cell lines are taking up approximately equal amount
of the drug (Fig 4.7). The various effects of beryllium observed at 100 µM in RKO cells
are insignificant compared to the response shown by A172 at 10 µM concentration (Fig
4.1, 4.3, 4.4, 4.5). These two observations, almost same amount of beryllium uptake but
difference in response of the two cell lines suggest that beryllium may be influencing a
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pathway that is present is A172 but not in RKO. This suggests that the difference in
uptake of beryllium is not a cause for the observed difference in the effects between the
two cell lines
DISCUSSION

Constant long term exposure to beryllium will show its effects as chronic
beryllium disease which in some cases may be lethal. Beryllium is carcinogenic at high
concentrations but has the ability to induce premature senescence at lower doses
(Coates SSA et al., 2007).
Our initial experiments with tumor cells and beryllium show that it is able to stop
tumor cells from proliferating (Figure 4.1). Beryllium shows difference in its effects
depending on the type of cell line. The decrease in cell proliferation is more in sensitive
cell line A172 than the resistant line RKO. Only the cells that are attached to the dish are
used to generate the cell count of viable cells. The decrease in cell count at lower doses
is not due the cell death as it appears from the graph (additional data not shown). The
lower cell counts in beryllium treated samples can be explained by arrest of cell division
at G1 phase (Figure 4.2). The major contributor for decrease in counts in the cell count
experiment is the decrease in cells that undergo division.
One significant event that occurs within 24 hours after treating tumor cells is
increase in p53 and p21 proteins (Figure 4.3). The change is more pronounced in A172
cells compared to RKO. p53 protein shows its effect on cell cycle by activating
transcription of p21, a very important protein downstream of the p53 controlled
senescent or apoptosis pathways.
The amount of available active p53 inside the cell is increased by
phosphorylation of residues at different positions with help of various kinases. These
changes prevent degradation of p53 resulting in its accumulation. Status of Ser 15
phosphorylation is verified to estimate stabilization of p53 (Shieh SY et al., 1997). We
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Figure 4-6 Beryllium does not cuase DNA damage

A. A172 cells were treated for 24 and 48 hour period with the above shown doses of
beryllium. Cells treated with 10 µM concentration of Etoposide and Camptothecin
for 24 hours along with UV dosed cells were used as positive controls. The lanes
with beryllium treated samples show no increase in H2AX ser 139 phosphorylation
compared to negative control lanes. The positive control samples treated with
Etoposide, Camptothecin and UV light show enormous increase in H2AX Ser 139
phosphorylation.
B. A172 cells treated with 0µM used as control and 10 µM or 300µM beryllium used as
test and 10 µM Etoposide as positive control were analyzed using
immunofluorescence microscopy. The cells were fixed, permeabilized and treated
with primary antibody against gamma H2AX and a FITC bound secondary anti body.
Double strand DNA breaks trigger phosphorylation of H2AX at ser 139 position and
will be seen as bright foci, as in case of Etoposide 10 µM treated cells.
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Figure 4-7 Differential uptake of beryllium is not a cause for difference in A172 and RKO
sensitivities
At 10 µM beryllium concentration, it appears that A172 cell line is taking up higher beryllium
compared to RKO cell line. But the 100 µM data shows clearly that difference in uptake of the
beryllium is not significant between the two cell lines.
2+
The wash control data demonstrates the efficiency of wash procedure in removing Be from the
exterior surface of cells. The cells used for 30 wash control are cultured in 0µM but exposed to
BeSO4 for 1 minute then washed according to protocol and prepared for ICP-MS analysis.
The data are presented as mean +/- Standard Deviation.
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found that beryllium treatment causes phosphorylation of p53 at ser15 (Figure 4.3C).p21
levels are increased by transcribing p21 mRNA which is regulated by stabilized p53. The
increase in p21 protein levels corresponds to the increase in p21 mRNA levels (Fig 4.4).
The amount of p21 mRNA is 135% more at 24 hours and 225% more at 48 hours
compared to control. The RKO cells show no change even a 100µM, 10 times higher
dose than the concentration required bringing about a response in A172. RKO cells have
functional p53 - p21 system which is evident from the response to UV and IR dosing
verified by western blotting and RT-PCR experimental data. These changes are in
agreement to a well documented observation that initial increase in p21 inhibits
progression of cell cycle in the cells (Di Leonardo, A. et al, 1994).
SA-β-gal is used as an important biomarker for senescence. It is found to be
increased only in senescent cells and not in actively dividing or terminally differentiated
cells (Dimri GP, 1995). Recent studies show that drug induced increase in levels of SAβ-gal can be used as marker for estimating the senescent like cell cycle arrest in cancer
cells. The increased level of senescence-associated beta-galactosidase seen in these
senescent cells is due to the accumulation lysosomal β-galactosidase (Lee BY et al.,
2006). Increased lysosomal activity is observed in the cells that are senescent stage
(Gerland et al., 2003). Our hypothesis that beryllium induces senescent-like state in
cancer cells is corroborated by the recent finding that suggests intracellular
concentration of beryllium may not be able to induce apoptosis (Ding J et al., 2009). We
have found that long term treatment of A172 cells with beryllium induces expression of
SA-β-gal (Fig 4.5). The level of SA-β-gal expressed is comparable to that seen in young
HFL-1 cells. RKO on the other hand did not show any change in SA-β-gal levels. No
change of SA-β-gal level in beryllium treated RKO samples is consistent with the actively
dividing cells seen in that cell line.
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The drugs that are used in therapy for cancer for their ability to induce
senescence usually cause DNA damage. The DNA damage subsequently results in
activation of p53 based pathway to induce senescence. DNA damage can be monitored
by checking the phosphorylation of ser 139 residue on histone H2AX (Rogakou EP et
al., 1998). We have used H2AX Ser 139 phosphorylation as marker for DNA strand
break to verify if beryllium was causing DNA damaging in the sensitive cell line i.e.,
A172. Cell cycle arrest-inducing low dose of BeSO4 at 10 µM and a very high dose of
100 µM and 300 µM were used. Results from both western blotting as well as
immunofluorescence suggest that beryllium does not cause any DNA damage.
The difference in magnitude of the effect of beryllium observed in A172 and RKO
is not due to difference in uptake of beryllium as evident from ICP-MS study. It is
possible that the difference is due to the variable genetic sensitivities of the cell lines. In
the present study we were able to confirm that beryllium is able to induce senescence in
sensitive cancer cell lines. The mechanism by which Be2+ is doing this is not yet clear but
the results indicate that the mechanism involves no DNA damage that is seen regularly
with other senescence inducing drugs. The unique ability of beryllium to activate
senescence signaling pathway through p53 without inflicting DNA damage makes it
novel tool to investigate the mechanism of senescence induction in greater detail.
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CHAPTER 5 CELL CYCLE INHIBITING EFFECTS OF BERYLLIUM ON
CANCER CELLS ARE P53 DEPENDENT
INTRODUCTION

Beryllium, when administered to cells in the form of beryllium salts was found to
inhibit the growth in human fetal lung fibroblast and rat hepatic cell lines. Cell cycle
arresting properties of beryllium were first reported by Hart and Skilleter et al (Hart et al.,
1982; Skilleter et al., 1983). Beryllium in the form of BeSO4 was reported as a new
premature senescence inducing agent in normal young Human Fibroblast (HFL-1) cells.
Further, it was demonstrated that BeSO4 was influencing the cell cycle progression while
causing an increase of cell cycle inhibitor protein p21 and a decrease in DNA synthesis,
resulting in an induced premature senescence. BeSO4 was found to increase the levels
of p53 and p21 and inhibit growth in normal human lung fibroblast (Lehnert et al., 2001).
It was also discovered that p53 protein binds to the promoter region of p21 thus
regulating its transcription in the presence of BeSO4 (Coates et al., 2007). In an earlier
study we have investigated the ability of BeSO4 to induce senescence like state in
susceptible cancer cell lines. BeSO4 was found to stabilize p53 and induce expression of
p21 followed by induction of senescence like state in some cancer cell lines with wild
type p53 without considerable effect on other cell types (Gorjala and Gary, 2010). This
observation suggested that presence of wild type p53 alone was not sufficient to elicit a
response to beryllium salt treatment.
p53 protein plays a key role in the intracellular signaling network in sensing the
DNA damage and regulating the cell cycle (Di Leonardo et al., 1994). p53 through p21
mediates senescence in normal cells and is also responsible for senescence in cancer
cells when exposed to drugs (Chang et al., 1999). p53 can be activated by various
stress stimuli, DNA damage, short telomeres or activated oncogenes. The activated p53
can induce expression of p21 which in turn can mediate cell cycle arresting actions (El41

Deiry et al., 1993; Xiong et al., 1993). Studies have established that p21 can be
expressed in both p53-dependent as well as p53-independent manner (Macleod et al.,
1995). Further it has been found that p21 can be up-regulated in p53 independent
manner but p53 is required for p21 induction in situations where DNA damage is caused
by radiation (El-Deiry et al., 1994; Michieli et al., 1994).
Beryllium has been shown to introduce G1-S phase cell cycle block (Skilleter et
al., 1983; Lehnert et al., 2001). Cyclin-dependent kinases (CDKs) are a family of protein
kinases that are periodically activated during cell cycle due to binding of proteins called
cyclins. DNA damage or other genotoxic stress induces p21Waf1/Cip1 which binds to
cyclin E-cdk2 complex. Binding of p21 to cyclin E-cdk2 complex results in competitive
inhibition blocking S-phase entry to cells due to hypophosphorylation of pRb (Morgan,
1996; Sherr and Roberts, 1995). Preliminary results from microarray data suggest that
beryllium causes a decrease in cyclin E2 mRNA levels (unpublished data).
A172 cells, a glioblastoma cell line, which are used for this study express wild
type p53 sequence and have functional p53 protein (Ishii et al., 2006; Jia et al., 1997;
Mirzayans et al., 2005). Beryllium is able to increase p53 and p21 in A172 cancer cells
without DNA damage (Gorjala and Gary, 2010). In the present study we have
investigated whether p21 induction and cell cycle arrest produced by beryllium is p53
dependent. We have used three different “knock-down” methods, siRNA, shRNA and
expression of E6 protein, to remove p53 protein or mRNA from cells. Short interfering
RNA (siRNA) is an approximately 20 nucleotide long synthetic double stranded RNA
molecule that can post-transcriptionally silence a gene. siRNA method has ready to use
reagents and is the quickest method to knock down a specific gene. The protocol can be
optimized to minimize off-target nonspecific effects but the knock down is transient and
potent for short term experiments. On the other hand short hairpin RNA (shRNA) has a
sequence inserted into viral vector plasmids. Expression of shRNA in target cells causes
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silencing of target gene expression. shRNA provides an alternative to avoid working with
RNA and can induce a stable expression. The disadvantages of using shRNA include
the need for time consuming cloning and the need for verification of insert. The third
method used is E6 protein expressed by HPV that binds to the p53 protein and promotes
its degradation in ATP dependent manner through ubiquitin-protease system (Scheffner
et al., 1990). Each of the knock down methods removes either the mRNA transcript or
functional protein from the cells. The result of each knock down method individually often
is not completely effective in removing the gene product. On the other hand the “knockout” methods involve deletion of the target gene. By using three knock down methods in
the same study we were able to complement the results from one method with the other
and get a complete picture.
MATERIALS AND METHODS

Cell lines and reagents
A172 (human glioblastoma) cells were from ATCC (Manassas, VA). Cells were
grown in RPMI 1640 with Gluta-MAX and 25 mM HEPES (Invitrogen-Gibco)
supplemented with 10% FBS (HyClone) and 1%

Antibiotic–Antimycotic (Invitrogen-

Gibco) at 37ºC in a 5% CO2 atmosphere. BeSO4. 4H2O used for dosing cells was from
Fluka (a division of Sigma-Aldrich).
A172-E6 cells are A172 cells transfected with pCMV-E6 expressing the human
papillomavirus 16 E6 gene. A172-neo cells are A172 cells transfected with a similar
plasmid without E6 (pCMV-neo) to serve as transfection control. Both A172-E6 and
A172-neo are established and characterized as described earlier (Xu et al., 2005) and
were kindly provided by Dr. J. Gregory Cairncross (University of Calgary, Calgary,
Alberta, Canada).
siRNA based p53 mRNA knockdown was done by using Validated Stealth RNAi
DuoPak (Cat # 45-1492). Additional reagents used in the procedure were Lipofectamine
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2000 (Cat # 11668-027) and OptiMEM reduced serum RPMI (Cat # 11058-02). Each of
the Stealth RNAi molecules from Stealth RNAi DuoPak were used at a final
concentration of 20 nM and Lipofectamine 2000 was used at 0.01 mg/mL. The reagents
were diluted from stocks in OptiMEM. Each 100 mm plate recieved 2.5 mL of mixture for
12 hours. The cells were then trypsinized and reseeded at required confluency and
dosed with BeSO4.
shRNA based p53 knock down was achieved by transducing A172 cells with p53
shRNA (h) Lentiviral Particles (Cat#sc-29435-V) and transduction control cells were
generated by using Control shRNA Lentiviral Particles (Cat# sc-108080) on A172 cells.
Successfully transfected cells were selected by growing them in RPMI with puromycin
followed by isolation of single cell clones.
Cell count experiment
50,000 cells were seeded to 60mm plate for each dose. The cells were given
change of media with BeSO4.4H2O at required concentrations. Cells were trypsinized by
adding 0.5mL of trypsin EDTA followed by incubation at 37ºC and 5% CO2 for 3 mins.
The cells were resuspended in 2.5mL of RPMI. 100µL of cell suspension was used for
cell counts. Remaining cell suspension was used to seed cells in to fresh 60mm plate at
predetermined split volume to maintain subconfluency. Cell counts were taken using a
Beckman Coulter Z1 counter.
mRNA quantification by RT-PCR
RNA from treated cells was isolated using RNeasy kit, cDNA was synthesized
and Real Time-PCR was performed using QuantiTect SYBR Green PCR reagents from
Qiagen. Primer pairs were, also from Qiagen - QuantiTect Primer Assay, QT00095431,
QT00079247, QT00062090, QT000060235, QT00041986, QT01012284 for human
beta-actin, human GAPDH, human p21(CDKN1A), human p53, human cyclin E1 and
cyclin E2 respectively were used. Thermal cycling and data collection was performed on
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a Bio-Rad iCycler. iCycler software was used to determine PCR efficiency for each
gene-specific primer set and to calculate the Starting Quantity (SQ) of gene-specific
mRNA in each sample. Data was analyzed according to the method described earlier
(Gorjala and Gary, 2010).
Western blotting
Cells ready for harvest were washed after RPMI was removed. Cell lysis was
performed in plates by addition of 300µL of M-PER (Mammalian Protein Extraction
Reagent, Pierce) supplemented with protease and phosphatase inhibitors. Total protein
concentration was determined by using a bicinchoninic acid (BCA) assay (Pierce) and
equal amount of total protein sample per well was resolved on precast Bis-Tris Midi Gel
and transferred to PVDF membrane. Immunoblotting was conducted using anti-p53
mouse monoclonal (sc-126, clone DO-1), anti-p21 mouse monoclonal (sc-6246,clone F5), anti-actin goat polyclonal (sc-1615) antibodies from Santa Cruz Biotechnology, Inc,
CA. Appropriate HRP-conjugated secondary antibodies were used and blots were
developed with ECL Plus (GE Healthcare) imaged on a Typhoon Variable Mode Imager
set to scan in fluorescence mode with a 457 nm laser and emission at 520 nm. Some of
the blots were developed using Immun-Star™ WesternC™ Chemiluminescence Kit and
images were taken using ChemiDoc XRS+ from Bio-Rad.
Cell cycle analysis by flow cytometry
After cell culture, the cells were fixed with 70% ethanol, treated with RNase, and
stained with 50µg/ml propidium iodide (PI). Cellular DNA content was determined from
PI fluorescence intensity using a Becton–Dickinson FACSCalibur flow cytometer and
Flowjo data analysis software for cell cycle phase determination.
DNA synthesis and total DNA content
Cellular DNA synthesis was measured from the incorporation of 5-bromo-20deoxyuridine (BrdU). Cells were grown in the presence or absence of BeSO4 for 72 h.
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Cells were allowed to grow for 61 h in 100mm plates. The cells were trypsinized,
counted and re-seeded into 96-well plates at constant number into each well. Two
identical 96-well plates were setup. The cells were allowed to and at the end of 72 hours
BrdU label was added. Label incorporation was allowed for 3.5 hours and 96-well plate
were processed and fluorescence was measured using a plate reader set to 340 nm
excitation, 465 nm emission.
RESULTS

Three methods to knock down p53 mRNA or protein
To generate A172 cell lines lacking p53 activity three different strategies were
employed.
Two different validated stealth siRNA sequences targeted to TP53 mRNA
(accession number NM_000546) coding region between 252-1433 were used to induce
knock down of p53 transcript. The resulting cells are referred to as KO1, KO2 and siRNA
control treatment cells as KO control. We observed on western blot that the transfection
target p53 protein is almost completely removed from the cells. The effect of siRNA
though transient was effective in keeping the levels of p53 down even at the end of
48hours (Fig 5.1a).
As second approach we established sub-clones of A172 cells by infecting them
with Lentiviral particles containing expression constructs encoding target-specific 1925nt shRNA to knockdown gene expression of p53. The sub-clones of A172
constitutively express shRNA specific for p53. After transduction, cells expressing the
constructs were selected under puromycin pressure. Single cell clones were isolated
and propagated. Western blotting done on cell lysates of the clone used for this study
(Fig 5.1b) show significantly reduced p53 protein compared to normal A172 cells. The
established p53 knocked down clones are called as LVp53KO and transfection control
clones as LVp53KOcontrol.
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Figure 5-1 Downregulation of p53 protein siRNA and shRNA

a.

b.

Two different validated stealth RNAi sequences (KO1 and KO2) were used to
knock down p53 mRNA in A172 cell lines. Western blotting was used to evaluate
levels of p53 and Actin protein in A172 normal, A172 KO1 and KO2 treated with
0 and 10 µM BeSO4 for 24 and 48 hours.
Reduced expression of p53 protein in A172 cells,LVp53KO. The p53 gene
expression is knocked down by using p53 shRNA (h) Lentiviral Particles.
Duplicate sample set is shown here.

47

Both the above methods work on mRNA to remove p53 transcripts from the cells. A third
strategy used was expression of E6 protein from human papillomavirus 16. The E6
protein expressed by HPV binds to the p53 protein and promotes its degradation in ATP
dependent manner through ubiquitin-protease system (Scheffner et al., 1990; Vogelstein
and Kinzler, 1992).
Functional p53 makes A172 cells sensitive to growth inhibition by beryllium
Beryllium was able to inhibit cell proliferation in the presence of functional p53
protein. A172 cells that were expressing p53 i.e., A172, A172 KO control (Fig 5.2a) and
A172, A172-neo in (Fig 5.2b) were very sensitive to 10 µM beryllium. Whereas cells with
p53 knocked down showed tolerance to beryllium relative to cells with functional p53.
Cumulative cell number of the three cell types A172 (functional p53), A172
LVp53KOcontrol, A172 LVp53KO was almost same under 0µM beryllium (Fig 5.2c). In
the presence of 10 µM beryllium the LVp53KO cells showed sustained increase in cell
number over a period of 12 days but the cell types with functional p53 showed cytostatic
response for up to 9 days followed by a decrease in cell number (Fig 5.2c).
Beryllium induced accumulation of cells at G1-S phase and decrease in DNA
synthesis is p53 dependent
BeSO4 causes G1-S phase block in A172 cells (Gorjala and Gary, 2010). Cell
cycle analysis by flow cytometry confirmed this result in A172 and A172-neo cell lines.
The percentage of cells in S phase at 0µM dose in A172 dropped from 15.1% +/- 1.1 to
5.3 +/- 1.1 in 10 µM treated samples. Similarly the percentage of cells in S phase in
A172-neo cell type changed from 9.4 +/- 1.1 to 1.2 +/- 0.2 between 0 and 10 µM doses.
However the percentage of cells entering S-phase changed from 13.3% +/- 0.7 to 10.8
+/- 0.4 with 10 µM beryllium treatment in A172-E6 cells which have low levels of
functional p53 compared to A172 and A172-neo (Fig 5.3a).
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Figure 5-2 Presence of functional p53 sensitizes cells to growth inhibition by beryllium

a.

b.

c.

A172 cells and p53 siRNA treated A172 cells (KO1, KO2, KO Control) were
cultured RPMI with 0, 3, 10, 30, 100 µM BeSO4 and counted at the end of 9
days and shown here as percent of untreated cells (mean ± SD) of respective
cell types.
A172 cells, E6 expressing A172 cells and A172 Neo cells were cultured in RPMI
with 0, 10, 30, 100 µM BeSO4 and counted at the end of 6 days. Counts are
expressed as percent on untreated cell number (mean ± SD) of respective cell
types.
A172 cells with functional p53 (A172 and lentiviral control) or with p53 knocked
down (Lentiviral p53 KO) were cultured in 0µM BeSO4 RPMI (left) and 10 µM
BeSO4 (right)for 12 days. Cumulative cell number (mean ± SD) was determined
every 3 days and cells were re-seeded to fresh plates to maintain sub
confluency.
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Figure 5-3 Beryllium induced accumulation of cells in G1-S phase and DNA synthesis
block requires functional p53 protein

The percentage of cells with p53 protein knocked down entering S-phase in the
presence of BeSo4 is more compared to cells with functional p53. This observation also
correlates with higher DNA synthesis activity in p53 knockdown cells compared to
normal cells.
A. A172 normal,A172-E6 and A172-neo cells were cultured in RPMI +/- 10 µM
BeSO4 for 72hours. Propidium Iodide (PI) stain was used to measure DNA
content using flowcytometry. Data is expressed as percentage of mean ± SD of
total cells number of counted from three replicate samples.
B. A172 cells were treated with siRNA to knock down p53 mRNA (KO1, KO2 and
KO control serves as siRNA treatment control). A172 cells and siRNA treated
A172 were cultured in RPMI with 0, 10, 30 µM BeSO4 for 72hours. Rate of DNA
synthesis was analyzed by using BrdU incorporation assay. Values are
expressed as mean ± SD of percent of A172 0µM BrdU fluorescence signal
measured
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DNA synthesis occurs during S phase of cell cycle. Beryllium can induce and
maintain a reversible decrease of DNA synthesis (Gorjala and Gary, 2010). A172, KO1,
KO2 and KO control cells were treated with10 µM beryllium for 72 hours. The rate of
DNA synthesis was measured using incorporation of BrdU, a thymidine analog(Fig 5.3b).
In normal A172 cells, the rate of DNA synthesis in 10 µM and 30µM BeSO4 cells
decreased to 15% +/- 2 and 15% +/- 2 of control cells. At 10 µM dose of beryllium A172
cells with p53 knocked down i.e., KO1 and KO2, showed a small decrease to 84% +/- 5
and 86% +/- 5 relative to A172 cells at 0µM.
Beryllium induced p21 increase is dependent on p53 protein
p21waf/cip is an important cyclin-dependent kinase inhibitor that regulates the
progress of cell cycle. p21 is known to function in both p53 dependent as well as
independent manner. To evaluate significance of p53 in the cell cycle inhibition response
of A712 cells to beryllium treatment, we have analyzed the mRNA and protein levels of
p21. p21 is a product of CDKN1A gene that is involved in cell cycle inhibition and a
target for p53 transcription factor.
A172, KO1, KO2 and KO control cells were cultured in RPMI with 0 and 10 µM
BeSO4. mRNA levels for p53 and p21 were measured using quantitative RT PCR. The
siRNA knock down of p53 gene expression was effective and is evident from p53 mRNA
decrease to 46.0% and 33.6% of control in KO1 and KO2 respectively but no change
seen in KO control cells (Fig 5.4). The p21 mRNA decreased to 55.4% and 34.9% of
control in KO1 and KO2 cells treated with 10 µM BeSO4 but did not change in control
and control KO cells. The A172 cells when treated with 10 µM beryllium showed 4 times
increase in p21 mRNA. In A172 KO1 and KO2 the p21 levels increased modestly to
122.99% and 91.84% of A172 control at 0µM treatments. Similar response was also
observed in A172-E6 cells showing a small change compared to control cells in which
p21 mRNA increased significantly (Fig 5.5). Although the expression of p53 mRNA in
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Figure 5-4 BeSO4 up-regulation of p21 in p53 dependent manner

A172 cells were treated with siRNA to induce p53 mRNA knock down. The cells are then
cultured in the presence of 0 or 10 µM BeSO4 for 48hours. mRNA levels of p53, p21,
Actin and GAPDH in each sample were quantified using RT-PCR. Housekeeping genes
Actin and GAPDH are expected to generate relatively constant amount of mRNA in
control and treatment samples. mRNA quantities of all genes quantified were normalized
relative to Actin mRNA and expressed as mean +/- SD of percent of A172 control
values.
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Figure 5-5 BeSO4 requires functional p53 for p21 mRNA increase

A172, A172 E6 and A172 Neo cells were treated with 0 or 10 µM BeSO4 for 48 hours.
mRNA levels of p21, Actin and GAPDH in each sample were quantified using RT-PCR.
Actin mRNA values were used for normalization.
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A172 cells did not increase in response to beryllium treatment, the protein levels were
higher (Fig 5.7).
p53 and p21 protein levels were analyzed in cell types generated by the three
different methods. The samples with p53 mRNA or protein knocked down showed less
p53 protein compared to control and the corresponding samples also showed decreased
p21 (Fig 5.7).
Cyclin E1 and E2 levels are inversely related to functional p53 protein levels
The basal level of cyclin E1 and cyclin E2 mRNA in A172-E6 cells was higher
than A172 control cells and showed no change of in response to 10 µM BeSO4
treatment. On the other hand the A172 cells exposed to 10 µM beryllium the level of
Cyclin E2 dropped to 8.9% of A172 controls while in A172-neo it decreased to 20.7% of
A172 control. Similar trend was observed for cyclin E1 with A172 control cells
expressing lower mRNA at 44.9% and neo cell type with 45.8% of A172 control when
exposed to 10 µM beryllium.
Looking at protein levels using western blot, we observed little cyclin E2 in A172
cells. Therefore we investigated other cell types with increased cyclin E2 expression
levels in order to verify that cyclin E2 changes could be measured in our system. MCF7
cells expressed detectable levels of both cyclin E1 and E2. Helmbold et al (Helmbold et
al., 2009) showed that untreated MCF7 cells express low levels of cyclin E1 and that
cyclin E1 levels increase dramatically 7 days after ionizing radiation (20 Gy) treatment or
doxorubicin (1 µM) treatment. A small increase of cyclin E1 protein was observed at the
end of 2 days in ionizing radiation treated samples compared to control cells that
received no drug treatment (Fig 5.8a). MCF cell line was used to ensure that we could
detect both cyclin E1 and E2. Cyclin E1 was not detectable in A172 and young HFL1cells (Fig 5.8b). p53 knock down samples did not show any changes in cyclin E2
protein even at 100 µM dose. However, A172 and LVp53KO control cells showed
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Figure 5-6 Cyclin E1 and E2 mRNA levels are lower in cells with high p53 protein

A172, A172 E6 and A172 Neo cells were treated with 0 or 10 µM BeSO4 for 48
hours. mRNA levels of cell cycle regulating proteins Cyclin E1 (CCNE1), Cyclin E2
(CCNE2) and housekeeping genes Actin, GAPDH in each sample were measured using
RT-PCR. Data are expressed as percent of A172 control mean +/- SD
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Figure 5.7 p21 protein expression is dependent on p53 protein

a. Control cells were normal A172 , Neo were transfection control A172 cells
and E6 were A172 cells expressing E6 protein that binds to p53 and
degrades it.
b. KO1 and KO2 represent two different siRNA sequences used to knock
down p53. Normal A172 cells were represented by control and KO
Control represents siRNA treatment controls
c. LVp53 are A172 cells that have shRNA to silence p53 mRNA, transduced
by using lentivirus. LV control are transduction controls and Control
samples are from regular A172 cells.
The cells were grown with 0 or 10 µM beryllium for 48 hours and protein
levels were analyzed by western blotting. Same amount of protein was
loaded to each lane.
In all three types of p53 knocked down A172 cells p21 expression is
dependent on functional p53 protein in the cell.
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Fig 5.8 Effect of BeSO4 on Cyclin E2 protein expression is correlated with p53 status in
A172 cell line

a. To verify if changes in cyclin E could be detected we used MCF7 cell line
in an attempt to replicate results from (Helmbold et al., 2009). MCF7 cells
were cultured with BeSO4 at 0, 10 and 100 µM doses in addition to
doxorubicin at 1 µM and ionizing radiation at 20Gy. Beryllium was
maintained in cell culture during the entire time period. Cells were
exposed to doxorubicin for 2 hours. The cells were harvested with MPER
at the end of 2 and 7 days. A172 cells were cultured for a period of 4 days
in 0,10 and 100 µM doses. A172 cells showed no detectable cyclin E1 but
a decrease in cyclin E2 was observed at 100 µM BeSO4 dose.
b. A172 cells, LVp53KO and LVp53KO control cells , MCF7 and HFL-1
young cells were cultured in the presence of BeSO4 for 4 days and total
cell lysate was analyzed for cyclin E1 and E2 proteins. The A172 and
LVp53KO control cells showed decrease of cyclin E2 at 100 µM dose.
HFL-1 cells showed no detectable cyclin E2 even at 10 µM dose.
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decreased cyclin E1 at 100 µM and HFL-1 cells showed no detectable level of cylin E2
at both 10 and 100 µM .
DISCUSSION:

Replicative DNA synthesis occurs during the S phase of cell cycle. BrdU data
(Fig 5.3b) shows that there is decrease in DNA synthesis in cells with functional p53
protein when treated with BeSO4. The decrease in DNA synthesis correlates with the G1
block as evident from cell cycle analysis (Fig 5.3a). Beryllium can cause a cytostatic
effect in cells with p53. The cells with p53 knocked down show some resistance to this
effect of beryllium (Fig 5.2c).
Be treatment causes phosphorylation of p53 at ser 15 (Gorjala and Gary, 2010).
p53 stabilization is correlated with the phosporylation of Ser 15 (Shieh et al., 1997). In
the presence of beryllium p53 binds to p21 promoter region (Coates et al., 2007).
However, p21 can also be induced in a p53 independent manner (Michieli et al., 1994).
Therefore we sought to determine whether p53 is necessary for p21 induction by
berylliuim salt.
Here we report that p21 induction by BeSO4 has been found to be p53
dependent (Fig 5.4,5.5, 5.7). We have observed that there is no significant change in
p53 mRNA but p53 protein is found to increase in response to beryllium treatment in
dose dependent manner (Fig 5.4, 5.7).
RNAi mediated removal of p53 mRNA from cells or inactivation of p53 by E6
expression leads to a significant decrease of p21 gene expression (Fig 5.4, 5.5). Lower
p21 mRNA in cells is reflected as lower p21 protein concentration in cells with p53
knocked down. p53 is required for p21 induction in situations where DNA damage is
caused by radiation (El-Deiry et al., 1994; Michieli et al., 1994). Beryllium induces p53
and p21 without any DNA damage (Gorjala and Gary, 2010). The data presented here
demonstrate that cells dosed with beryllium induce p21 in a p53 dependent manner.
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Cyclin E2 is different from cyclin E (now called cyclin E1) in that it follows slightly
different pattern of activity during cell cycle (Gudas et al., 1999; Lauper et al., 1998).
Cyclin E2 mRNA levels peak at the G1-S transition phase. Normal human foreskin
fibroblast cells were found to show increased cyclin E2 mRNA when p53 is degraded by
E6 expression in these cell lines (Zariwala et al., 1998). In a microarray study of p53mediated transcriptional repression, CCNE2 was identified as one of the 111 genes that
were down-regulated at least 2 fold after p53 over expression (Spurgers et al., 2006).
Using microarray our group has found that CCNE2 is downregulated following beryllium
treatment (unpublished data). Therefore, we sought to validate this finding using
qualitative RT-PCR. If there is a decrease in expression of CCNE2 in response to
beryllium we wanted to determine if it is p53-dependent beryllium response.
We have found that A172 cells treated with BeSO4 with functional p53 show a
significant decrease of cyclin E2 mRNA, to a lesser extent cyclin E1. The cells with p53
inactivated show little change in cyclin E1 and E2 mRNA levels. The change of Cyclin
E1 and E2 mRNA levels do not correlate with the corresponding protein expression. We
found that cyclin E1 is not detectable in the total cell lysates of A172. A172 is glioma cell
line and cyclin E1 is absent in human brain cells while cyclin E2 is observed in high
levels(Zariwala et al., 1998). Using the same amount of total protein, beryllium resistant
MCF7 cells expressed cyclin E1 protein that could be visualized using western blot. In
A172 cells the changes in cyclin E2 protein in response to beryllium treatment could be
seen after 4 day exposure at 10 and 100 µM (Fig 5.8a, 5.8b). In A172 cells The mRNA
changes could be seen at the end of 48 hours upon exposure to 10 µM dose(Fig 5.6).
Our experiments with A172 cells at shorter time points did not show observable changes
in cyclin E2 protein levels (data not shown). The normal lung fibroblast cells HFL-1
showed decrease of cyclin E2 protein at 10 µM dose for 4 day exposure (Fig 5.8b).
BeSO4 is known to increase p53 protein in HFL-1 cells (Coates et al., 2007).
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In the present study we have shown that p53 knock down in A172 is resulted in
increased expression of cyclin E2 mRNA and protein. This correlates with E6 expressing
cells entering S phase of cell cycle with higher DNA synthesis compared to cells normal
A172 with functional p53 (Fig 5.3). All the evidence presents a possibility where BeSO4
may be activating a branch of p53 network that inhibits cell proliferation via p21 and also
simultaneously decreasing the level of cyclin E2 mRNA initially and protein at later
stages to induce G1-S block.

60

CHAPTER 6 BERYLLIUM INDUCED CASPASE 3/7 DOES NOT CAUSE
APOPTOSIS
INTRODUCTION

p53 is an important determinant in cellular response to stress. The apoptosis
inducing function of p53 is under intensive study and its transcription dependent and
independent pathways to induce apoptosis have been identified. The extrinsic pathway
uses death receptors of tumor necrosis factor family of receptors (TNF-R) (Ashkenazi
and Dixit, 1998). Activation of these receptors leads to cascade of events resulting in
inducing activity of caspase 3, which in turn commits the cell to apoptosis. On the other
hand p53 dependent intrinsic pathway is activated in the event of DNA damage and
results in release of cytochrome c from mitochondria. cytochrome c forms a complex
with apoptotic protease-activating factor 1 and procaspase 9 to activate other
executioner caspases like caspase 3 (Gross et al., 1999; Li et al., 1998; Nicholson and
Thornberry, 2003).
The extrinsic pathway for apoptosis is activated by p53 dependent transcription
of genes for Fas, DR5 and PERP. Among these Fas is an important member of TNF-R
family of receptors that plays a crucial role in extrinsic pathway. p53 transcription factor
binds to promoter of the Fas gene there by inducing its mRNA expression (Muller et al.,
1998). Unpublished data from microarray experiment on HFL-1 young cells treated with
and without beryllium showed that some genes related to apoptosis are activated. FAS
gene is the most up regulated in the list of genes in Table 6.1 (unpublished data, data
not shown). One of the potential therapeutic strategies used in treatment of cancer
involves using Fas and Fas ligand which are members of death receptor pathways.
Here we present data that shows that caspase activation due to beryllium may
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NCBI
Reference
Sequence

Gene

Definition

NM_001065

TNFRSF1A

tumor necrosis factor receptor
superfamily, member 1A

NM_001188

BAK1

BCL2-antagonist/killer 1

NM_003842

TNFRSF10B

tumor necrosis factor receptor
superfamily, member 10b

NM_005921

MAP3K1

mitogen-activated
kinase kinase kinase 1

NM_138578

BCL2L1

BCL2-like 1

NM_033292

CASP1

caspase 1, apoptosis-related
cysteine peptidase (interleukin
1, beta, convertase)

NM_000043

FAS

Fas (TNF receptor superfamily,
member 6)

protein

Table 6-1 Apoptotic genes upregulated in beryllium treated HFL-1 cells

List of genes up-regulated in HFL-1(Y) treated +/- 10µM beryllium in microarray analysis
(unpublished microarray data from Gary Lab; gene expression changes have not yet
been evaluated by RT-PCR for verification).

not be leading to apoptosis. BrdU wash out experiment data shows that cells can revert
back to active DNA synthesis state after the berylluim is removed from media. The data
from XTT assays demonstrates that mitochondrial function is intact in the presence of
beryllium. However, from the cell count data it is observed that there is decrease in cell
number over long periods of exposure to higher concentration of beryllium. The
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apoptosis signals initiated by death receptor pathways converge on the effector
caspases like caspase 3 (Ashkenazi and Dixit, 1998; Schulze-Osthoff et al., 1998).
Caspase 3 and 7 that are crucial for execution of apoptosis are activated in both
extrinsic or receptor mediated and intrinsic or non-receptor mediated apoptotic pathway
(Elmore S, 2007). The results documented in this chapter are from experiments setup in
an attempt to verify if there is any apoptosis due to caspase 3/7 activity in the presence
of beryllium.
MATERIALS AND METHODS:

Cell Culture
HFL-1 (human lung fibroblasts), Wild type A172 (human glioblastoma)and RKO
(human colon carcinoma) cells obtained from ATCC, were used for experiments. The
cell lines were propagated RPMI1640 with GlutaMAX supplemented with 10% fetal
bovine serum and 1% PSF. The cells were cultured in 100mm dishes at 37ºC with 5%
CO2. 0.05% trypsin EDTA was used for trypsinizing the cells when splitting.KO1 and
KO2 – p53 knock down was achieved using siRNA as described in chapter 5.
Drug treatment:
BeSO4.4H2O from Fluka was used to prepare a stock solution. Beryllium stock
solution was diluted to required concentration in RPMI just before dosing.Staurosporine
was from Calbiochem (Cat# 569396) and Sigma (Cat# S6942). Camptothecin from
Sigma (Cat #C9911) was prepared according to instructions by dissolving 10mg in 1mL
DMSO.Etoposide from Sigma (Prod. No. E1383) was prepared as a 50mM stock
according to instructions. Q-VD-OPH (Cat#OPH 109) was purchased from Enzyme
systems products Solon, Ohio.
Caspase assay
A predetermined number of cells are seeded into 96 well plate and cultured with
or without drug. Activity of caspase 3/7 was measured with Caspase Glo 3/7 Assay (Cat
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#G0890) and ApoTox-Glo™ Triplex Assay (Cat #G6321) from promega. When 384 well
plate is used for assay the cells are cultured in 60mm plates with or without drug for the
required length of time. The cells are then trypsinized and a specific volume from each
plate is transferred to 384 well plates in triplicate.
TUNEL assay
Was performed with Fluorescein-12-dUTP based method optimized in house.
The cells were analyzed using Flowcytometry. Detailed protocol adapted from original
protocol by Heatwole VM (Heatwole, 1999) is given in appendix VI.
DNA synthesis, Metabolism and Cell number
Cells were grown in RPMI in the presence of required concentrations of BeSO4
on 100mm plates. Each dose was setup in triplicate. After 64 hours cell were trypsinized
and seeded into a 96well plate at the rate of 26000 cells per well. Cells from each plate
were seeded in triplicates. Three identical plates were setup. Remaining cells were
seeded into new 100mm plates for day 6 experiment. The cells in 96 well plate were
allowed to attach for additional 8 hours. At the end of 72 hours cells were washed and
BrdU incorporation assay was performed according to kit instructions from EMD
Biosciences/Calbiochem. Similarly plates for XTT assay and CyQuant cell proliferation
assay were also performed on the respective plates.
Statistical Analysis
Data sets with two dosage groups at each time point were analyzed by unpaired
t-test, two tailed. Data sets with more than two groups were analyzed using one-way
ANOVA with a post-hoc Bonferroni's multiple comparision test (P < 0.05 considered
significant).
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RESULTS

Staurosporine, Camptothecin and Etoposide induce caspase 3/7 in A172 and RKO
Both A172 and RKO cell lines show increase in caspase 3/7 activity in response
to treatment with apoptosis inducing drugs staurosporine, camptothecin and etoposide.
The major difference in response between the cell lines is that RKO shows huge
increase of caspase 3/7 at early time points of 12 and 24 hours whereas the increase in
A172 cell line is at later time points of 24 and 48 hours (Fig 6.1).
In A172 cells staurosporine was able to produce an increase caspase3/7 activity
of 421% of control in first 12 hours which further increased with time reaching upto
1029% of control by the end of 48 hours. Camptothecin and etoposide however showed
caspase3/7 activity of approximately twice the control values at 24 hour time point which
increased to 743% and 530% of control by 48 hour time point.
RKO cells show an opposite pattern to A172 with highest activity of caspase 3/7
in first 12 hours by staurosporine at 871% of control which decreased to 232% of control
by 48 hour time point. Campothecin used at 10µM concentration induced caspase 3/7
within first 12 hours and is maintained approximately at the same level even at the end
of 48 hour time. Etoposide induced caspase 3/7 in RKO cells in a manner that is
different from the other two drugs showing a very small increase of 150% of control in
first 12 hours followed by a maximum increase upto 618% of control by 24 hours which
is maintained at 537% by the end of 48 hour time point.
Beryllium induces caspase 3/7 in A172 but not RKO
Response of the two cell lines A172 and RKO to staurosporine, camptotheicn
and etoposide is almost same as in Fig 6.1. RKO showed no change of caspase 3/7
activity in response to beryllium treatment both at 24 and 48 hours (Fig 6.2). BeSO4 was
able to induce a dose dependent increase of caspase 3/7 at 48hrs in A172 cells. A 10
µM dose of beryllium was able to induce 303% of control increase of activity of caspase
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Figure 6-1 Staurosporine, Camptothecin and Etoposide induce caspase 3/7 in both
A172 and RKO
2500cells of A172 and 2000 cells of RKO were seeded into each well of a 96well plate.
Each dose was seeded in triplicate. Media with staurosporin at 1µM, camptothecin at
10µM and etoposide at 50µM was supplied at 48hrs, 24hrs and 12hrs before the assay
time point. Caspase 3/7 activity was measured using Caspase Glo assay from promega.
Apoptosis inducing drugs staurosporin, camptothecin and etoposide cause increase of
caspase of approximately same amount in both A172 and RKO cell lines but at different
time points. The data are presented as mean +/- Standard Deviation. Statistically
significant differences are indicated with * P < 0.05.
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Figure 6-2 Beryllium induces caspase in A172 but not RKO
2500cells of A172 and 2000 cells of RKO were seeded into the wells of a 96well plate. Every
dose was seeded in triplicate. Media +/- drug was supplied at 48hrs and 24hrs before the assay
time point. The data are presented as mean +/- Standard Deviation.
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3/7 which is comparable to effect of 50µM dose etoposide at 347% of control. 100 µM
and 300 µM doses of beryllium increased activity of caspase3/7 to 832% and 1484% of
control. 1 µM staurosporine and 10 µM camptothecin caused an increase of 915% and
625% of control respectively.
Beryllium can induce caspase 3/7 in A172 and HFL-1(Y) but not in HFL-1 (S)
Both at 24 and 48hr time point beryllium was not able to induce caspase in HFL1(S)cells (Fig 6.3). In rapidly dividing A172 and HFl-1(Y) cells

beryllium induced

caspase3/7 in dose dependent manner at 48hrs. The total amount of caspase3/7
induced in A172 is higher compared to HFL-1(Y).
Functional p53 is required for beryllium to induce caspase3/7
From the results (Fig 6.4) we can see that KO1 cell type has abnormally high
caspase3/7 activity. This may be caused by the duplex oligo used in siRNA treatment for
p53 knock down. It should be noted that the morphology of KO1 cells was also abnormal
compared to A172, KO1 or KO control.
As seen in earlier experiments the A172 cells show dose dependent increase of
caspase3/7 activity. The KO control cell type also shows similar pattern. The KO2 cell
type with p53 knock down shows almost no increase of caspase3/7. At 300 µM dose, it
can be seen that there is difference in activity of caspase3/7 between A172 control
(587.5%), KO control (479.8%) and KO2 (265.6%).This data suggests a possibility that
functional p53 may be required for beryllium based increase of caspase activity.
Beryllium induced caspase3/7 may not cause cell death in A172 and HFL-1(Y) cells
Q-VD-OPH is an anti-apoptotic drug that can inhibit activity of many different
caspases including capase 3. The results (Fig 6.5) demonstrate that Q-VD-OPH at 50
µM concentration was able to inhibit activation of caspase induced by beryllium even at
a high dose of 100 µM. The response of both A172 and HFL-1(Y) cells is following the
same pattern.
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Figure 6-3 Beryllium can induce caspase 3/7 in A172 and HFL-1(Y) but not in HFL-1 (S)
2500cells of A172 and 2000 cells of HFl-1(Y) at passage 14 were seeded into each well of a
96well plate. HFL-1 (S) cells at passage 33, that are not dividing were seeded at 16,000 cells per
well. Each cell line for each dose was seeded in triplicate. Media +/- drug was supplied at 48hrs
and 24hrs before the assay time point. The results are plotted as percent of control on log scale
to present the differences between cell lines clearly. The data are presented as mean +/Standard Deviation.
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Figure 6-4 Functional p53 is required for beryllium to induce caspase3/7
A172 cells treated with siRNA to knock down p53, KO1 and KO2 along with KO control and
regular A172 cells were cultured in 60mm plates with +/- beryllium. Each dose for each cell type
setup in triplicates. At the end of 48hrs, 20µL of the cell suspension from these plates(including
the floating cells) was seeded into 384well plate. Contents from each plate seeded to 3 wells.
ApoTox-Glo™ Triplex Assay was used to generate this data. This kit combines caspase glo kit
with a Live / Dead cell detection assay. This enables measuring of 3 parameters in each well. The
caspase values were normalized with ratio of live cell to dead cells. All values expressed as
percent of Control at 0µM beryllium. Abnormally high caspase 3/7 in KO1 0µM may be caused
by the duplex oligo used in siRNA treatment. Unlike KO2 and KO control. The data are presented
as mean +/- Standard Deviation.
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Figure 6-5 Beryllium induced caspase can be inhibited by QVDOPH

6.5a and b: 2000 cells of A172 and 2500 cells of HFL-1(Y) were seeded into each well
of 96well plate. Two 96 well plates were setup for each cell line. The cells were dosed
with RPMI +/- beryllium and beryllium + Q-VD-OPH (50µM). At the end of 48hrs cyquant and caspase assay were performed on the respective plates. The data are
presented as mean +/- Standard Deviation.
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In the presence of beryllium alone or beryllium and Q-VD-OPH we can see that
there is decrease of cell number with increasing concentration of beryllium. The cell
number measurement was done using Cy-Quant assay.
Taken together these results show that the decrease in cell number in the
presence of beryllium may not due by apoptosis caused by caspase3/7 activation.
Beryllium induced caspase does not lead to Apoptosis
Beryllium at 10 µM did not cause any labeling by TUNEL assay as compared to
control cells which did not receive any drug treatment (Fig 6.6). At a higher concentration
of 300 µM there is around 10% higher signal compared to control. On the other hand the
positive controls DNAase I treated cells (39%), camptothecin (10 µM – 67% and 100 µM
– 86%) and staurosporine (69%) treated cells show a very high percentage of cells
undergoing apoptosis as detected by increase in signal. The difference in TUNEL
positive signal between beryllium treated and positive control treatments indicate that
beryllium may not be inducing apoptosis to the extent as expected by the caspase3/7
activation.
Beryllium induced inhibition of DNA synthesis is reversible
In the presence of 10 µM BeSO4 by the end of 72 hours there is significant
decrease of DNA synthesis as measured by BrdU incorporation assay (Fig 6.7A). For
the same time point and dose, the activity of mitochondria (Fig 6.7B) or the total DNA
content (Fig 6.7C) did not change comparably. However, when the cells are continued in
culture without beryllium the DNA synthesis activity showed recovery reaching 50% of
control treatment by the end of 6 days and by 9 days the recovery was almost 100% of
control (Fig 6.7A). There is no change in mitochondrial activity and total DNA content at
day 6 and 9 (Fig 6.7B, 6.7C).
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Figure 6-6 Beryllium induced caspase does not lead to Apoptosis
A172 cells were treated with 10µM and 100µM beryllium for 48hours, Camptothecin 10µM and
100µM for 48 hours and staurosporine 0.2µM for 24 hours were processed according to TUNEL
assay protocol for flowcyotmetry. The data are presented as mean +/- Standard Deviation.
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Figure 6-7 Beryllium induced inhibition of DNA synthesis is reversible
A172 cells were treated with 0µM, 1µM, 3µM and 10µM beryllium for 72hours as described in
methods section and day 3 readings were taken for BrdU incorporation, XTT and CyQuant. The
cells were cultured further in RPMI without beryllium and readings were taken on day 6 and day
9. The data are presented as mean +/- Standard Deviation.
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DISCUSSION

The data in chapter 4 shows that beryllium may not be causing cell death. The
microarray data showed increased expression of apoptosis related genes. Due to this
the possibility of apoptosis had to be investigated. To use as positive controls we have
selected 3 drugs (staurosporine, camptothecin and etoposide) that are known to induce
apoptosis.
The exact mechanism of action of staurosporine, a protein kinase inhibitor, is not
clearly understood. But studies point to a possibility that it can induce apoptosis at early
stages through caspase-dependent mechanism and at later stages can employ a
separate signaling pathway that is caspase-independent (Belmokhtar et al., 2001; Zhang
et al., 2004). Camptothecin forms a complex with DNA and topoisomerase I resulting in
DNA damage. It is specifically potent in S phase cells (Hsiang et al., 1985; Hsiang et al.,
1989). Etoposide is a DNA topoisomerase II inhibitor and functions by blocking DNA
topoisomerase resulting in DNA strand break. Etoposide requires p53 for its apoptosis
inducing function (Grandela et al., 2007; Karpinich et al., 2002). The time points at which
these drugs induce activity of caspase may be different from each other due to
difference in mechanism of action. The same reason may also explain the difference in
the time points of caspase induction between cell lines. However, the three drugs were
able to induce caspase 3/7 activity in both the sensitive A172 and the resistant RKO cell
line. The apoptosis inducing effect of DNA replication interfering drugs, camptothecin
and etoposide, as measured by caspase3/7 activity is seen at earlier time point in RKO
cells compared to A172. This may be due the shorter cell doubling time of RKO cell line.
The standard apoptosis inducing drugs were able to induce caspase in RKO cell
line within 24 hours, BeSO4 did not show comparable effect on this beryllium resistant
cell line. The caspase 3/7 activity was dose dependent in A172 cell line and is seen at
48 hour time point. The timing of caspase 3/7 activity induction is similar to camptothecin
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and etoposide suggesting that beryllium may be following the similar pathway used by
these two drugs. However it has to be noted that in chapter 4 it was demonstrated that
there is no DNA damage as seen by phosphorylation of γ-H2AX. The caspase 3/7
activity measured in the presence of BeSO4 in HFL-1 young (Y) and senescent (S) cell
lines (Fig 6.3) suggests that active cell division is required for BeSO4 to induce
casase3/7 activity. Additionally the BrdU incorporation assay on A172 cells shows that
beryllium induced inhibition of DNA synthesis is not permanent (Fig 6.7A). Also there is
no decrease in metabolic activity of cells in the presence of beryllium as seen from the
XTT data (Fig 6.7B).
TNF receptor superfamily member, Fas gene is upregulated by beryllium dosing
as seen in preliminary data from microarray experiment. Evidence from other studies
that fas gene can be upregulated by p53 (Muller et al., 1998). Apoptosis initiated by
death receptor through extrinsic pathway also results in activation of caspase 3/7.
Caspase3/7 activity measured in p53 knocked down cells provides some evidence that
functional p53 may be required for activation of caspase3/7, especially at higher doses
of 100 and 300µM beryllium. In the siRNA system used for this experiment one of the
duplex oligos used to generate KO cell type KO1 may be causing activation of caspase
3/7.
The distinct feature of apoptosis is that the initiation of caspase cascade results
in DNA fragmentation. In any case if only caspase initiation is observed without any sign
of other characteristic features of apoptosis like DNA fragmentation such a cell death
cannot qualify as apoptosis (Takemura et al., 2001). The TdT-mediated dUTP Nick End
Labeling assay called as TUNEL assay, labels the ends of the degrading DNA in
apoptotic cells using the enzymatic activity of polymerase terminal deoxynucleotidyl
transferase (TdT) (Gorczyca et al., 1992; Gorczyca et al., 1993). The flowcytometry
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based TUNEL data shows that beryllium at 10 µM does not cause any labeling. The data
suggests that DNA fragmentation is not taking place in the presence of beryllium.
Recent discoveries show that there are caspase-independent mechanisms that
can cause apoptosis. Discovery of XIAP based inhibition of caspase 3 showed that
activation of caspase 3 does not necessarily always induce apoptosis (Deveraux et al.,
1999; Scott et al., 2005). Studies have shown that XIAP based caspase 3 inhibition
protects the cell from CD95 (Fas/Apo-1) mediated apoptosis (Bratton et al., 2002). We
have used a well-known pan caspase inhibitor Q-VD-OPH to verify if the reduction in cell
number seen at higher doses of beryllium is due to cell death caused by caspase
induction. Q-VD-OPH has antiapoptotic properties

and is not toxic to cells high

concentration (Caserta et al., 2003). From the data (Fig 6.5 A, 6.5B) it is evident that 50
µM Q-VD-OPH was able to effectively inhibit the activity of caspase 3/7 at all
concentrations of beryllium used in the study. The cyquant assay data used to calculate
cell numbers on a replicate plate setup in parallel shows that the Q-VD-OPH inhibition of
caspase 3/7 is not able to rescue the cells from cell death at higher concentrations of
beryllium (Fig 6.5C, 6.5D).
The scope of this study is limited to check if the increase in caspase 3/7 is
resulting in apoptosis of beryllium sensitive cell line. In this study we have checked an
early and a late markers of apoptosis i.e., caspase 3/7 activity and DNA fragmentation.
These markers give information concerned with nuclear and cytosolic compartments of
the cell. To completely evaluate the effect of beryllium with respect to apoptosis further
study is required using RT-PCR and western blotting techniques to evaluate the
expression of mRNA and proteins of early markers like bcl-1, BAX, TRAIL. These
proteins are concerned with changes in mitochondria. Flow cytometry based evaluation
of membrane changes using Annexin V and mRNA, protein data related to Fas receptor
activity will give a complete picture.
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CHAPTER 7 SUMMARY AND FUTURE DIRECTIONS
SUMMARY

1.

Beryllium salt can inhibit cell proliferation in susceptible cancer cell lines.

2.

BeSO4 causes phosphorylation of p53. This stabilizes p53 leading to its

accumulation in the cell.
3.

Other changes induced by BeSO4 treatment include increase of p21,

Senescence-associated beta-galactosidase activity. G1-S cell cycle block and
decreased DNA synthesis are also observed.
4.

In spite of changes in intracellular activity that resembles DNA damage response

pathway there no DNA damage caused by BeSO4.
5.

Increase of p21 and cell cycle arrest in response to BeSO4 treatment are p53

dependent.
6.

p53 is required in sensitive cancer cells for regulating cyclin E2 expression in

response to BeSO4 treatment.
7.

Caspase 3/7 activity was found to be increased in beryllium sensitive cancer cells

treated with BeSO4. But there is no correlation between caspase 3/7 activity to number
of cells undergoing apoptosis.
FUTURE DIRECTION

1.

Survey of cancer cell lines in chapter 3 revealed that different cell lines have

different levels of tolerance to BeSO4 dosing. ICP-MS data in chapter 4 shows that the
uptake of beryllium by sensitive and resistant cell types is almost equal thus, suggesting
that the amount of beryllium inside the cells may not be the reason for differences in
sensitivity to BeSO4. We have also found that functional p53 is required for induction of
cell proliferation arrest in response to BeSO4 treatment. The survey included wild type
and mutant p53 expressing cell lines. No correlation was observed between p53 status
and beryllium resistance. The mechanism by which some cell lines can resist beryllium
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is not clear. A detailed survey which includes a wide range of cell types from different
tissue sources may help in identification of the pattern.
2.

A nominal decrease in mRNA expression of cyclin E1 and E2 is observed in

A172 cells by the end of 48 hours of BeSO4 treatment. Such a change is not seen in the
corresponding protein levels by 48 hours (data not shown). However, cyclin E2 protein
levels decreased by the end of 4 days. Cyclin E1 protein levels were below detection
limit of the antibodies used in western blotting. Cyclin E1 and E2 protein expression
begins at the same time during G1-S transition. The peak expression and degradation of
cyclin E1 arrive early compared to cyclin E2 (Lauper et al., 1998). Studies have shown
that ubiquitin dependent proteolysis ensures early degradation of cyclin E1 (Won K and
Reed S., 1996). However, not much research has been done related to cyclin E2.
We have also observed that altered cyclin E2 mRNA levels in beryllium treated
cells are dependent on p53. CCNE2 is one among the cell cycle regulatory genes that is
identified as a possible target for miR-34 miRNAs. mir-34 family of miRNAs that are in
turn regulated by p53 (He L et al ., 2007). The details of a possible pathway through
which p53 dependent regulation of cyclin E2 operates are not yet clearly known. A
detailed study to investigate the mechanism that regulates the activity of cyclin E2
through p53 will be contribute to overall understanding of the cell cycle arresting effects
of BeSO4.
3.

Preliminary data from microarray experiments showed that FAS gene is

upregulated in response to BeSO4 treatment. It has been found that p53 can bind to Fas
gene promoter (Munsch et al., 2000). In the present study we have shown that functional
p53 is required for growth arresting effects of beryllium. An earlier study published by
our lab group has demonstrated that in response to BeSO4 treatment p53 functions like
a transcription factor, binds to the promoter region and induces p21 mRNA expression
(Coates SSA et al., 2007). Validation of microarray results related to FAS gene
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upregulation, followed by gene expression studies using p53 knock out varieties of cell
lines will allow us to test whether FAS gene expression in the presence of BeSO4 is also
p53 dependent. We have also observed an increased caspase 3/7 activity in response to
BeSO4 treatment. The pathway leading to increase in caspase 3/7 activity in BeSO4
treated sensitive cell lines is not yet mapped. Since the protein encoded by FAS gene
plays an important role in extrinsic pathway for apoptosis further investigation into the
FAS gene related results from microarray data will be a good starting point in elucidating
the caspase 3/7 activation pathway.
4.

Increase of caspase3/7 did not induce apoptosis in BeSO4 treated samples. In

this study, changes in levels of activated caspase3/7 have been verified using CaspaseGlo 3/7 assay only. Additional assays comparing the total caspase 3 to the amount of
activated caspase in the presence and absence of BeSO4 are required. These assays
will help getting an accurate picture and also to validate the results from Caspase-Glo
3/7 Assay.
It may be possible that inhibitor of apoptosis proteins (IAP’s) are involved in
protecting the cells form caspase 3/7 in the presence of BeSO4. Some studies have
shown that in p53 mediated apoptosis, the increase of p53 protein correlates with
decrease of XIAP, a potent member of IAP family (Mohapatra et al., 2005; Zou et al.,
2012). An investigation directed towards the activity of IAPs in BeSO4 treated samples
may provide an answer to the failure of apoptosis in the presence of activated caspase
3/7.
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Appendix I

Characterization of an alternative +/- p53 human glioma
model system (U87MG)

BACKGROUND

A172, U87MG cell lines and their corresponding variants transfected to express
E6 protein and transfection control sequence were obtained from Dr. Gregory
Cairncross, University of Calgary, Alberta T2N 1N4, Canada (Xu et al., 2005). Both cell
lines were tested for sensitivity to beryllium using cell count method. A172 cell line data
is used in chapter 5. U87MG cell line data is documented here.
EXPERIMENT 1

Objective
To check the sensitivity of U87MG, U87MG-E6 and U87MG-Neo cell lines’ to
beryllium.
Method
The cells are exposed to selected range of beryllium concentrations at 0,
10,30,100,300 micro molar range for a period of 9 days. The cell counts are taken at the
end of 3rd, 6th, and 9th day. Cells were diluted and reseeded to maintain in sub-confluent
state.
The initial cell number to be seeded is 90,000 cells/plate. It is known from earlier
experiments that U87MG cell line grows slow so higher cell number is seeded instead of
regular 75000 cells/plate at 3ml per plate for this experiment. After the cells are allowed
to attach for a period of 24 hours, the plates are shuffled, labeled with concentration fo
beryllium and +/- beryllium RPMI is supplied to cells. One set of plates seeded for Day 0
counts are trypsinized and counted to get the starting cell number.
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Cell count and reseeding procedure
Old media is removed and cells are washed with P.B.S one time.
0.5 mL of trypsin EDTA is added to the cells and plate is incubated for 3 minutes
at 37°C. 2.5 mL of RPMI is added to inactivate the trypsin and cells are suspended in
RPMI. 100 µL of cell suspension is transferred into a coulter counter cup filled with 9.9
mL of isotone.
7 mL of RPMI with 8/7times the required concentration of BeSO4 is aliquoted to
pre-labeled 15 mL tubes. After taking 100 µL for cell counts, 1 mL of the cell suspension
is added to the respective 15 mL tubes with BeSO4 RPMI, this gives us 1:8 diluted cell
suspension of which 3 mL was seeded to new pre-labeled 60 mm dishes.
The above procedure is followed for reseeding and counting cells on day 3,6 and
9. On day 9 experiment is terminated.
Result
From the data obtained it can be seen clearly that U87MG-E6 cells are able to
tolerate BeSO4 presence better compared to the control cell types. This result suggests
that functional p53 may be required for the effects of beryllium to be seen (Fig 1).

82

Figure 1 U87MG Cal, Neo and E6 cell counts
Over a period of 9 days U87MG-E6 cell type is able to withstand presence of beryllium compared
to Control cell types. The abnormally high reading on day 9 for U87MG-E6 at 300µM
concentration is an experimental error. The data are presented as mean +/- Standard Deviation.
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EXPERIMENT 2

Objective
To verify the p53 dependence of p21 expression in response to beryllium in
U87MG, U87MG-E6 and U87MG-Neo cell lines
Method
All the three cell lines are dosed with 0, 10µM and 100µM BeSO4 for 48hours
and harvested using MPER with protease and phosphatase inhibitors.
Result
p21 expression is p53 dependent in U87MG cells and is dose dependent in
response to BeSO4 treatment (Fig 2).

Figure 2 U87MG Cal, Neo and E6 Western blots
Cal cells are regular U87MG, U87MG-E6 express E6 protein that binds to p53 protin making it
inactive and U87MG-Neo are transfection control cells.

EXPERIMENT 3

Objective
To verify p53 dependence of p21 gene expression in U87MG cells.
Method
U87MG, U87MG-E6 and U87MG Neo cells were treated with BeSO4 at 0,10 and
30 µM BeSO4 and RNA extraction was done at the end of 48hours.
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Result
p21 mRNA expression is p53 dependent in U87MG cells and is dose dependent
in response to beryllium treatment (Fig 3)

Figure 3 U87MG Cal, Neo and E6 p21 gene expression RT PCR data
Cal cells are regular U87MG, U87MG-E6 express E6 protein that binds to p53 protein making it
inactive and U87MG-Neo are transfection control cells. mRNA quantification was done using realtime PCR method. The data are presented as mean +/- Standard Deviation.

References
Xu GW, Mymryk JS, Cairncross JG. (2005) Inactivation of p53 sensitizes astrocytic
glioma cells to BCNU and temozolomide, but not cisplatin J Neurooncol 74:141-149.
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Appendix II

Characterization of a spontaneously-arising Be-resistant
clonal derivative of A172

BACKGROUND

IsoB11/17RS and IsoB11/9’RS cell types were generated from normal A172 cells
by Dr. Ronald Gary. The procedure followed briefly is as follows. Normal A172 cells
were grown in Be RPMI for long duration. The surviving cells were propagated resulting
in A172 cells that have developed resistance to beryllium. The cell count experiment was
done on IsoB11/17RS and IsoB11/9’RS cell lines along with normal A172 cells as
controls for comparison.
Objective
To verify if IsoB11/9’RS to beryllium have developed resistance to higher
concentrations of beryllium compared to A172 cells.
Method
The cells are to be exposed to 0,1,3,10,30,100,300, 1000, 3000,10,000 µM
doses of BeSO4 for a period of 9 days. The cell counts are taken at 3rd day, 6th day and
9th day. The cells are seeded in 60 mm dishes at 75000 cells/plate with each plate
receiving 3 mL cell suspension. Day 3,6,9 cells counting and reseeding is done as
described earlier.
Result
i)

Iso B cell types of A172 are resistant than normal A172 cells (Fig 1)

ii) Iso B 11/9’RS appeared to show more resistance to Be than Iso B11/17RS
on day 3 but by Day 9 Iso B11/17 was more resistant (Fig 1)
iii) Iso B11/17RS appeared to grow faster than Iso B11/9’ RS ( Fig 2). This is
supported by the cell doubling time values and general observation during
cell culture
iv) Cytostatic concentration (Fig 3)
86

Cytostatic Conc

Cell type

30µM

Iso B 11/17RS

30µM

Iso B 11/9’RS

10µM

A172 (01/22/07)

Table 1 Cytostatic concentrations for Iso cell types
The lowest conc that is showing same cell number for 3,6,9 day counts is taken
as cytostatic (Fig 3). However for all cell lines then next two conc’s also appear
to maintain approximately same cell number.

Cell type

Doubling time
29 hrs

Iso B 11/17RS

35 hrs

Iso B 11/9’RS

28 hrs

A172 (01/22/07)

Table 2 Cell doubling times
These values are calculated based on the time points at which the cell count procedure
was started on Day 3,6, and 9
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Figure 1 Iso cell types are resistant to beryllium compared to A172
Day 3,6 and 9 cell count data is plotted as percent of control cells (0µM of respective cell
lines)shows that the Iso cell types of A172 cell line were able to adapt to beryllium and
have higher resistance compared to regular A172. The data are presented as mean +/Standard Deviation.
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Figure 2 Cell doubling time of Iso cell type is greater than A172
The absolute cell counts with dilution factors of 8 for day 6 and 64 for day 9 incorporated
into cell counts were plotted. Day 0 counts 48200, 31400 and 63466 for A172, IsoB
11/17 RS and IsoB 11/9' RS respectively. By end of day 3 it can be seen that A172 cell
were replicating faster compared to the Iso cell types. Among the Iso cell types Iso B
11/17 RS were having lower cell doubling time. The data are presented as mean +/Standard Deviation.
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Figure 3 Cytostatic concentration of beryllium
Dilution factor included total cell numbers are plotted against beryllium concentration for
Day 3,6 and 9. For A172 the minimum concentration of beryllium that can stop cells from
dividing is 10µM. The cytostatic concentration for Iso cell types is 30µM. The data are
presented as mean +/- Standard Deviation.
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Appendix III

Evaluation of p53 and p21 status and response to
beryllium treatment in BV cell lines

BACKGROUND

Four different cell lines were obtained from Dr. Bert Vogelstein’s lab. These are
HCT116 cells (Human colon carcinoma cells), one of these being a p53 knock out and
another is p21 knock out along with two respective controls.
EXPERIMENT 1

Objective
To check the sensitivity of all 4 cell lines to beryllium dose.
Method
The cells are exposed to 0, 1, 3, 10, 30, 100, 300, 1000 ,3000 ,10,000 µM doses
of Be for a period of 6 days. The cell counts are taken at 3rd and 6th day. The experiment
was set up in 60mm dishes. 75000 cells/plate at 3 mL per plate were seeded on day -1.
Cell count procedure
Old media is removed and cells are washed with P.B.S one time.
0.5 mL of trypsin EDTA is added to the cells and plate is incubated for 3 minutes
at 37°C. 2.5 mL of RPMI is added to inactivate the trypsin and cells are resuspended in
RPMI. 100 µL of cell suspension is transferred into a coulter counter cup filled with 9.9
mL of isotone and used for getting cell counts.
3rd day counts
7 mL of RPMI with 8/7 times the required concentration BeSO4 for is prepared in
the pre-labeled 15 mL tubes.
100 µL of cell suspension is used for cell counts. 1ml of the cell suspension is
added to the respective 15ml tubes with BeSO4 RPMI, giving 1:8 diluted cell suspension
of which 3 ml will be seeded to new pre-labeled 60 mm dishes.
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6th day counts
Old RPMI is removed and cells are washed with P.B.S one time. 0.5mL trypsin is
used for 3 minutes at 37ºC. Trypsin is inactivated and cells are suspended by using 2.5
mL RPMI. 100 µLof cell suspension is transferred into9.9 mL of isoton for cell counting.
Result
Due abnormal counts obtained at various concentrations for each cell line no
conclusions could be drawn from the data (Fig 1).
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Figure 1 Cell count data for BV cells
Cells were trypsinized and resuspended in RPMI with beryllium concentration
calculated to compensate dilutions. 100µL of cell suspension was mixed with 9.9mL
isoton solution. Coulter counter was used to get cell counts. Due to large standard
deviation in cell numbers and abnormal counts obtained the data could not be used
to arrive at any useful conclusions. The data are presented as mean +/- Standard
Deviation.
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EXPERIMENT 2

Objective
To identify p53, p21 knock outs and controls.
Method
1. Western blot
2. Real time PCR
1. Western Blot
Cells for BV#2, #4, #17, #8 were setup in 100mm plates and harvested when the
confluency reached 95% using RIPA extraction protocol. Extracted samples were mixed
with 5x Lamelli sample buffer and boiled for 3 minutes. BCA assay was performed on
remaining cell supernatant to determine total protein concentration.
PAGE was performed using 9% acrylamide gel. Primary antibody treatment
given using p21 and p53 antibodies over night. Corresponding secondary antibody
treatment done and blots were developed using ECL+ reagent. Typhoon was used to
scan the blot.
Result

Figure 2: p53 and p21 status in BV cell types
BV#2 – p53 band absent - p53 knock out cell type; BV#4 – p21 band absent p21 knock out cell type; Both BV#17 and BV#8 are expressing p53 and p21 protein
and are control cell types.
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2. Real time PCR
Cells for each cell type, BV#2, #4, #17, #8, were cultured in 100mm plates and
RNA was extracted from the cells. Reverse transcription was done to generate cDNA.
cDNA diluted and used in Real Time PCR reactions to screen for p21 gene expression
along with Actin and GAPDH.
Result
Extremly high concentration of BeSO4 at 1 mM was not able to induce p21 gene
expression in p53 knocked down BV#2 cell type (Fig 3). At 100 µM BeSO4 dose the
control cell line BV#8 did not show any response in the form of p21 mRNA expression.
The results suggest that BV cell lines i.e., HCT116 are resistant to beryllium dosing and
p21 expression in these cell is p53 dependent in response to beryllium treatment.

Figure 3 p21 gene expression in p53 knock down BV cell line
Cells were cultured in +/- Be RPMI for 48 hours at 0, 10, 30 and 1000µM
concentrations. The starting quantity (SQ) of mRNA was measured using real time
PCR techniques. Values are normalized with Actin and expressed as percent of
control. The data are presented as mean +/- Standard Deviation.

BV#2 cell line is p53 knock out variety and BV#8 is a control cell line. As
seen from data the p21 gene is not expressed in BV#2 cell line even at very high
concentraton of beryllium dose of 1mM. BV#8, with functional p53, required a very
high dose to induce a response in the form of p21 gene expression increase.
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Figure 4 p21 gene expression in p53 knock down BV cell line
The experiment in Figure 3 is repeated with different concentrations of beryllium
here. Exposure time is 48hours. The data shows that BV#8 ,the control cell line with
wild type p53 gene, is able to resist effect of beryllium upto 100µM. The p53 gene
expression at 300µM is doubled compared to control. On the other hand BV#2, the
p53 knock out (p53KO) variety has no expression of p53 gene. The data are
presented as mean +/- Standard Deviation.
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Appendix IV

Optimization of siRNA for p53 knock down and

generating stable p53 knock down shRNA A172 clones
EXPERIMENT 1
BACKGROUND

TP53 validated stealth RNAi (Cat No. 45-1492) was purchased from Invitrogen.
The kit contains two Validated Stealth RNAi Duplex oligos. Cells treated with duplex 1
and 2 are labeled as KO1 and KO2 respectively.
Objective
To test if the new TP53 validated stealth RNAi is able to induce efficient knock
down of p53 expression.
Method
HFL-1 young cells at passage 16, hTERT HFL-1 and A172 cells were cultured in
60mm plates and treated with validated stealth RNAi duplex oligos according to kit
instructions. The cells were then treated with beryllium and western blotting method was
used to verify presence of p53 protein.
Result
BLOCK-iT fluorescent Oligo was used to get an assessment of the transfection
efficiency. The fluorescein-labeled duplex localized in nucleus as expected (Fig 1).
Validated stealth kit was able to induce p53 knock down efficiently in the three
different cell types tested. The knock down was maintained over a period of 48 hours
(Fig 2).
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Figure 1 Nuclear localization of fluorescent tagged Oligos
Left panels show the phase contrast images of the fluorescent field shown on right.
Fluorescent image is taken with FITC filter having 494nm excitation and 519nm
emission filters.
hTERT HFL-1 (A) and A172 (B) were treated with BLOCK-iT and images taken at
the end of 14 hours.
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Figure 2 p53 protein screening in KO cells using western blot
A172, HFL-1 young and hTERT HFL-1 cells were treated with validated stealth RNAi to
induce p53 knock down and then cultured for another 24hours (Day1) and 48hours (Day
2). The total protein concentration in HFL-1(Y) and hTERT HFL-1 samples was low so
the samples used without normalization. But the Actin band shows that these samples
were loaded at almost same total protein concentration. A172 samples were normalized
using BCA assay.
EXPERIMENT 2
BACKGROUND

The TP53validate steath RNAi kit was effective in inducing knock down of p53 in
the different cell types tested. However, It was observed that cell morphology changed
considerably after they receive Stealth RNAi treatment. According to the kit protocol the
duplex sequences are required to be mixed with Lipofectamine 2000 and Optimem
media. To improve the performance of kit by reducing damage to cells an experiment
was designed to optimize the concentration of lipofectamine 2000 and duplex oligos.
Objective
To identify optimum concentration of duplex oligos and lipofecatmine 2000 that
results in effective knockdown of p53 without causing changes in cell morphology.
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Method
A172 cells were treated with the following combinations of lipofectamine and
duplex oligos. 100% refers to kit recommended concentration.
100 % Oligo + 100% Lipofectamine 2000
50 % Oligo + 50% Lipofectamine 2000
100 % Oligo + 50% Lipofectamine 2000
Cells were then harvested using MPER at the end of 48, 72 and 96 hours. The
samples were normalized using BCA assay and western blotting was done to check for
p53 levels. As a control sample extract from A172 cells treated with beryllium was used.
Result
The combination #2 having 50% concentration of oligo as well as lipofectamine
was effective as 100% concentration upto 3 days. The cell death and morphology
changes were lower than 100% concentration. At 4 days both 100% and 50% dosed
cells showed recovery of p53 activity. It was decided to use 50% concentration for all
future experiments with repeat dosing at the end of 72 hours for experiments that require
p53 knock down to be maintained for longer periods.

Figure 3 Optimization of Lipofectamine 2000 and Oligo concentrations
100% refers to A172 cells treated with Kit recommended concentration (combination 1),
50% lanes have cells treated with combination 2 at 50% of kit recommended
concentrations, 50-100% lanes refer to samples from cells that were dosed with 50%
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Lipofectamine 2000 and 100% Oligo, combination 3. Combination 3 samples were not
run on gel due to limited number of wells on gel. Cells receiving 100% of lipofectamine
2000 showed severe morphology changes and higher cell death. MPER lysed samples
are resolved on PAGE and probed with p53 (DO-1) antibody
EXPERIMENT 3
BACKGROUND

Integrating specific short hairpin RNA (shRNA) constructs into genomic DNA can
induce targeted gene knock down. We have used p53 shRNA (h) Lentiviral Particles (sc29435-V) along with Control shRNA Lentiviral Particles (sc-108080) as negative control,
from santa cruz biotechnology, inc, to generate stably transfected A172, HFL-1 and
hTERT HFL-1 cells.
Method
8000 cells of each cell type were suspended in 200µL of RPMI and into 96 well
plate. The cells were allowed to attach overnight. The lentiviral particles were diluted in
RPMI with polybrene (Sigma Cat No. 107689) to get MOI of 0.5, 1, 2,4, 6 and 8. After an
overnight incubation regular viral RPMI was replaced with regular RPMI. Puromycin at
750ng/mL in RPMI was used to select and propagate successfully transfected cells.
Cells were tranfered to 60mm plates when wells in 96 well plate reached 90%
confluency. Cloning cylinders (Sigma Cat No. C1059-1EA) were used to select single
cell colonies for HFL-1 and A172 cells. The clones were further propogated and
maintained under selection pressure using puromycin RPMI. hTERT HFL-1 cells used in
this experiment were generated under puromycin selection. So the puromycin based
selection in this experiment is not guaranteed to select for p53 knock down. So hTERT
cells from high MOI wells of 96 well plate are saved.
The clones were verified for p53 knockdown using western blotting.
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Result
The western experiment confirmed successful knock down of p53 protein in the
clones selected. The transfected cells showed two bands for p53 with the lower band
corresponding to the band seen in normal A172 sample. The lower molecular weight
band is of lower intensity compared to control transfected cells. It has to be noted that
single band was seen in other western blot experiments done with these A172 clones
using a higher percentage gel.

Figure 4 p53 protein screeing of A172 p53 shRNA knock-down clones
Lentiviral treatment was able stably integrate shRNA to introduce p53 knockdown in the
selected clones. hTERT HFL-1 cells were previously selected under puromycin and the
cells may be a mixture of p53 knock down and p53 normal cells. A172 48 hour beryllium
treated cell sample was used as a reference for p53 protein.
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Appendix V

Beryllium on the activity of GSK 3 beta

BACKGROUND

Work done by previous graduate student included study of the effect of beryllium
on the activity of glycogen synthase kinase-3beta (GSK 3β). The western blot results
presented in this chapter are an extension of her work.
EXPERIMENT 1

Objective
To screen different cell lines for expression of GSK 3β and phosphor-Glycogen
Synthase (pGS).
Method
A172, S91, PC12, RKO,MCF7 and HFL-1 cells were treated with beryllium 30and
100µM, lithium

20mM,

1-Azakenpaullone - AKPL – 10µM and 5-Iodo-indirubin-3'-

monoxime – INDI - 20µM. MPER with protease and phosphatase inhibitors was used to
harvest the cells at the end of 48hours.
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Result

Figure 1 Expression of total GSK, pGSK3β and pGS in 6 different cell lines
Samples from all cell lines are not properly normalized. Both GSK-3α (~51 kDa) and
GSK-3β (~47 kDa) proteins are seen in GSK-3 α/β panel. It appears that HFL-1 and S91
cell lines may be having different levels of the enzyme.

With respect to pGS and pGSK3β ser9 general observation is that both Synthetic
inhibitors and Lithium were able to inhibit phosphorylation of GS compared to beryllium.
Both Synthetic inhibitors and Lithium were able to induce phosphorylation of GSK3β at
serine 9. The response of all cell lines to the different treatments is not same. Most of
the HFL-1 samples and INDI samples were loaded to give maximum total protein load
per well due to low protein concentration.
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EXPERIMENT 2

Objective
To evaluate the influence of beryllium on the activity of GSK 3β as compared to
Lithium and synthetic inhibitors.
Method
Phosphorylation of Glycogen Synthase and Tau, the substrates of GSK 3beta,
will be used as measure of increase or decrease of the GSK 3β enzyme activity.
A172, HFL-1 Young cells at passage 19 and PC12 were treated with Beryllium 10,30 and 100µM, Lithium – 10, 20, 30mM, 1-Azakenpaullone - AKPL – 10µM,
Alsterpaullone - ALPL – 10µM. Cells were harvested using MPER with protease and
phosphatase inhibitors at the end of 24 and 48 hours.
1-Azakenpaullone and Alsterpaullone are synthetic inhibitors of GSK 3β (Leost et
al., 2000).
The samples were probed for pGS, Tau, pTau and actin.
Result
Images obtained from western blotting were faint and not clean thus making
band identification difficult. The images below are labeled for sample lanes but not for
specific bands of the proteins.
The molecular weight marker shown for reference is for 4-12% gels as provided
by manufacturer but the gels used for the experiment are 10% gels.
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Figure 2 Tau(C-17) protein expression in A172, HFL-1 and PC12
A172, HFL-1 and PC12 cells were treated with beryllium, Lithium and synthetic inhibitors
as described in methods. The MPER extract of these cells was normalized using BCA
assay. Protein samples are resolved using PAGE and probed with Tau(C-17) antibody.
A172 and HFL-1 blots have almost no bands. May be due to low protein conc combined
with much lower levels of Tau in these cell lines. PC12 samples show some faint bands.
The duplicate set of samples for PC12 were also run on gel and also pTau levels were
probed in PC12 samples only (Figure 2). The expected molecular weight for Tau(C-17)
is 46-80 kDa.
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Figure 3 pTau (Ser 396) in PC12 cells
The duplicate set of samples from PC12 in figure 1 are probed with Tau(C-17) antibody.
2 and 3 are blots for PC12 replicate set of samples probed for pTau (Ser 396). The
expected molecular weight for pTau (Ser 396) is 45-68 kDa.
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Figure 4 Actin levels to check total protein normalization
Actin reprobe on phospho GS blot shows that some of the samples have very low
protein. It indicates inefficient transfer or problem with primary antibody treatment.
Molecular weight of Actin is approximately 43 kDa
REFERENCES
Leost M, Schultz C, Link A, Wu YZ, Biernat J, Mandelkow EM, Bibb JA, Snyder GL,
Greengard P, Zaharevitz DW, Gussio R, Senderowicz AM, Sausville EA, Kunick C,
Meijer L. (2000) Paullones are potent inhibitors of glycogen synthase kinase-3beta and
cyclin-dependent kinase 5/p25 Eur J Biochem 267:5983-5994.
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Appendix VI

TUNEL assay protocol

Reagent List
Equilibration buffer: Dilute 5x Terminal Transferase buffer.
TdT:

30U/uL

from

TERMINAL

DEOXYNUCLEOTIDE

1500U

Promega

Cat#M1875
Required at 30U per reaction according to protocol
PBS from HyClone Cat# ATH 32652
2x SSC: Dilute the 20x SSC solution left over from promega kit in DI water.
4% paraformaldehyde: prepared from paraformadehyde solid (Sigma P6148).
Weigh 1.6g into 35mL P.B.S. Heat solution on hot plate set to 1 or 2. Use thermometer
to monitor temperature at 65ºC. Use magnetic stirrer to stir the solution. Cover the
beaker with aluminum foil to avoid splatter. When the solution turns clear stop stirring
and allow cooling. Carefully measure the volume of solution remaining in the beaker and
make up volume to 40mL. Store in 50mL tube at 4ºC. 4% paraformaldehyde is diluted to
required concentration in P.B.S.
0.2% Triton X100: Sigma Cat# T9284 - Mix 80uL + 40mL P.B.S
70% ethanol: 95% Denatured Ethanol (Cat# BDH1158-4) is diluted to 70% by
mixing 29.4mL of alcohol with 10.5mL of P.B.S.
DNase I : From Biolabs cat# M0303S. Stock concentration is 2000U/mL. Diluted
in DNase I buffer to 1U/reaction
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Nucleotide mix
Required Stock
Conc
Conc
Fluorescein-12-dUTP

50uM

1mM

dATP
Tris-HCl pH 7.6

100uM
10mM

1mM
10mM

Fisher Scientific Cat No.:
FERR0101
TQAC131- omega Bio-tek VWR
Secondary stock diluted to
1mM from 100mM stock in
Tris-Hcl 10mM pH7.6

TdT labeling mix
Stock

Equilibration buffer

Nucleotide mix

5x
Use
prepared
above

TdT enzyme

30U/uL

Required for 1 Rxn
Terminal
Transferase
Buffer
Promega Cat#M1893
Dilute to half with DI water to get
2.5x, use 100uL per reaction
mix
10uL for each reaction
TERMINAL DEOXYNUCLEOTIDY
1500U Promega Cat#M1875
Use 1uL for each reaction

Procedure
Fixing cells
1. Cells grown in tissue culture plates are trypsinized by exposing cells to 0.05%
trypsin for 3 minutes at 37ºC followed by deactivating with used RPMI collected
into a pre-labelled tubes before adding trypsin. The cell suspension was
collected into a prelabelled 15mL tubes.
5. The cell suspension is centrifuged at 300xg, 4ºC for 6minutes.
6. Supernatant is removed and cell pellet is gently dispersed by tapping the tube.
7. Cells are washed twice in P.B.S.
8. P.B.S is removed and tube is tapped gently to disperse the cells.
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9. 1mL of 1% paraformaldehyde is added to the cells and incubate on ice for
20minutes.
10. Paraformaldehyde is removed by centrifuging cells at 300xg, 4ºC fror 5 minutes.
11. P.B.S wash is given to cells twice
12. After removing P.B.S, 70% cold ethanol is added to cells.
13. The cells are stored at 4ºC till they are processed by TUNEL assay.
TUNEL assay
14. Remove ethanol form samples by centrifuging and wash the cells twice with
P.B.S.
15. Start processing DNase samples first.
16. Equilibrate cells in equilibration buffer for 10minutes.
17. Remove buffer by centrifuging cells at 300xg, 4ºC for 5 minutes.
18. Add DNase I enzyme and incubate at room temperature for 10 minutes.
19. Remove DNase I enzyme by centrifuging at 300xg, 4ºC for 5 minutes and wash
cells with P.B.S one time.
20. Prepare nucleotide mix and TdT labeling mix as required for the number of
samples.
21. To all samples add equilibration buffer and leave at room temperature for
10minutes.
22. Centrifuge and remove excess buffer.
23. Add 100µL of TdT mix to each tube and incubate at 37ºC for 1 hour 45 minutes.
24. Add 500µL of 10mM EDTA to stop the reaction.
25. Centrifuge at 300xg for 10 minutes.
26. Wash cells with P.B.S twice and remove excess P.B.S by centrifuging at 300xg
for 10minutes.
27. Resuspend cells in 100µL P.B.S and transfer the cells into flowcytometry tube.
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28. Save the tubes on ice and process using flowcytometer set to read FITC label.

** It was observed that FITC label can interfere with PI stain readings. It is
preferable to prepare a parallel set of samples for DNA content analysis instead of using
FITC cells to double label with PI stain.
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